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Summary 
In eukaryotes, transcription of protein-coding genes and many non-coding RNAs relies 
on RNA polymerase II, a common set of general transcription factors (GTF), namely 
TFIIA, -B, -D, -E, -F, -H, -S, and coactivator complexes such as Mediator. The GTF are 
required for core promoter recognition, promoter opening, transcription start site 
recognition and initial RNA synthesis. The large multiprotein complex Mediator 
promotes preinitiation complex (PIC) formation at the core promoter by bridging gene-
specific activators bound to upstream DNA elements to the basal transcription 
machinery. The 7-subunit Mediator head module plays a pivotal role during PIC 
formation, contacting Pol II-TFIIF, TATA-binding protein (TBP), TFIIB, and TFIIH.  
During this work a combination of X-ray crystallography, yeast genetics, biochemical 
assays, chromatin immunoprecipitation and genome-wide expression profiling was 
used to elucidate the submodular architecture and molecular mechanisms underlying 
Mediator head function. The conserved functional head submodules Med8C/18/20 and 
Med11/22 were identified and their distinct functions characterized. A conserved 
flexible anchoring mode to the head module was demonstrated for both submodules. 
While the non-essential Med8C/18/20 is required for low transcription levels of a 
specific subset of nonactivated genes, mutations in the essential Med11/22 submodule 
had a more pleiotropic effect on gene expression. Structure-guided mutagenesis of 
Med11/22 identified a highly conserved surface patch required for stable PIC formation 
in vitro and in vivo. Furthermore, the determined crystal structure of Med11/22 revealed 
an unexpected homology to the Med7/21 middle module subcomplex. Structure 
predictions identified a total of 9 out of 17 Mediator core subunits and two metazoan-
specific subunits sharing the heterodimeric four-helix bundle fold of Med11/22. During 
evolution this common structural building block appears to have duplicated and 
diversified to generate new protein interaction surfaces and thus accommodate the 
need for more complex regulatory mechanisms.  
Furthermore, reliable nuclear extract based assays for in vitro transcription and PIC 
assembly on native yeast promoter templates were established and optimized. The 
assays were used in several collaborations to characterize the role of individual 
factors/subcomplexes during Pol II transcription. In addition, a label-free mass 
spectrometry approach was used to identify factors depending on the Mediator head 
module for core promoter binding.  
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1 Introduction 
1.1 RNA polymerases 
The central dogma of molecular biology was first postulated by Francis Crick (Crick, 
1970). It describes the directional flow of genetic information from deoxyribonucleic 
acid (DNA) via ribonucleic acid (RNA) to proteins (Figure 1). The underlying 
fundamental biological processes of DNA replication, transcription and translation are 
found in all three kingdoms of life.  
 
 
 
Figure 1: The central dogma of of molecular biology  
 
 
Transcription, the process of synthesizing RNA from a DNA template, is carried out by 
DNA-dependent RNA polymerases (RNAP). In 1960, four laboratories had 
simultaneously discovered RNAP in E. coli lysate (Hurwitz et al, 1960; Stevens, 1960), 
rat liver nuclei (Weiss & Gladstone, 1959) and extracts from pea (Huang et al, 1960). In 
general, RNAPs can be divided into single-subunit and multisubunit enzyme families. 
The two families lack any sequence or structural homology and are probably the 
product of convergent evolution (Cramer, 2002a). Single-subunit RNAP are found in 
bacteriophages (e.g. T3 and T7) and mitochondria while multi-subunit RNA 
polymerases are found in all three kingdoms of life. Whereas bacteria and archaea rely 
on a single RNAP for RNA synthesis, eukaryotic cells contain at least three distinct 
enzymes (Roeder & Rutter, 1969). RNA polymerase I (Pol I) is located in the nucleoli 
and synthesizes 5.8S, 18S and 28S ribosomal RNA (rRNA). RNA Polymerase II (Pol II) 
is located in the nucleoplasm and synthesizes the messenger RNA (mRNA) of all 
protein coding genes, small nucleolar RNAs (snoRNAs) and some small nuclear RNAs 
(snRNAs). Pol III is also located in the nucleoplasm and synthesizes transfer RNAs 
(tRNAs), 5S rRNA, some snRNAs and other small RNAs. The recently discovered 
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plant-specific Pol IV and Pol V are dedicated to the formation and maintenance of 
heterochromatin through small interfering RNAs (siRNAs) (Lahmy et al, 2010).  
Although multisubunit RNAP differ widely in their subunit composition and molecular 
weight (Table 1), the structural core and enzymatic mechanism is conserved in all three 
kingdoms of life (Cramer, 2002b; Hirata & Murakami, 2009; Ream et al, 2009).  
 
Table 1: Subunit composition of multisubunit RNAP from all three kingdoms of life  
table adapted from (Cramer, 2002b; Hirata & Murakami, 2009; Ream et al, 2009) 
a Subunits shared between Pol II and other RNAP are highlighted in bold red 
b (Geiger et al, 2010)  
 
 
Differences in peripheral subunits of the RNAP and regulatory factors reflect the 
complexity of the respective system. In bacteria, RNAP initiation relies on a single 
regulatory factor sigma, which recognizes promoter sequences and recruits the 
enzyme directly (Mooney et al, 2005). In archaea, two factors, TFB and the TATA-
binding protein (TBP), are essential for transcription initiation (Geiduschek & 
Ouhammouch, 2005). The much bigger eukaryotic RNA polymerases depend on large 
sets of regulatory factors that differ between Pol I, Pol II and Pol III (Roeder, 1996).  
The highly regulated transcription of protein-coding genes by Pol II relies on a plethora 
of factors, including general transcription factors (GTF), negative and positive cofactors 
including chromatin modifying factors and coactivator complexes, elongation factors, 
RNA processing factors and termination factors (Hahn, 2004; Svejstrup, 2004). The 
unique C-terminal domain (CTD) of the largest subunit of Pol II serves a flexible binding 
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platform for many of these regulatory factors. The CTD consists of multiple highly 
conserved heptapeptide tandem repeats of the sequence Tyr1-Ser2-Pro3-Thr4-Ser5-
Pro6-Ser7 (Allison et al, 1985; Corden et al, 1985), which are heavily phosphorylated 
during transcription (Cadena & Dahmus, 1987). CTD truncations to less than 8 
heptarepeats or mutations of the phosphorylation sites Tyr1, Ser2 or Ser5 are lethal in 
yeast (West & Corden, 1995). Changes in the CTD phosphorylation pattern were 
shown to orchestrate the association of different sets of regulatory factors required 
during different phases of transcription (Phatnani & Greenleaf, 2006).  
 
 
1.2 The RNA polymerase II transcription cycle 
1.2.1 Initiation and the general transcription factors 
Eukaryotic transcription by Pol II has been structurally and biochemically characterized 
in detail.  
 
Figure 2: RNA polymerase II transcription cycle 
The main phases of the transcription cycle are colored orange, important events of regulation are 
highlighted in yellow. The circle in the middle depicts the occurrence of the events in relation to the 
position on the gene. GTFs = general transcription factors; ORF = open reading frame (Image courtesy of 
Stefan Dengl, Gene Center Munich). Adapted from (Hahn, 2004; Svejstrup, 2004) 
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Pol II transcription follows the so-called transcription cycle (Figure 2), which is divided 
into initiation, elongation, termination, and reinitiation (Hahn, 2004; Svejstrup, 2004). 
Each phase is regulated and requires a specific set of factors.  
Transcription initiation is a multi-step process involving over a 100 different 
polypeptides (Sikorski & Buratowski, 2009; Thomas & Chiang, 2006; Venters et al, 
2011). First, gene-specific activator proteins (activators) recognize and bind their 
cognate DNA motif, which is often located within the upstream-activating sequence 
(UAS). Activators can bind to the UAS of multiple genes to generate a highly 
coordinated regulation of gene expression. However, often a gene is controlled by the 
action of multiple activators, leading to combinatorial regulation. Next, chromatin 
remodelers/modifiers and coactivators, such as ISWI, RSC, SWI/SNF, NuA4, RSC, 
INO80, SAGA and Mediator, are recruited to alter the chromatin environment and 
promote preinitiation complex (PIC) formation at the core promoter (Figure 3) The PIC 
comprises Pol II and the GTFs, namely TFIIA, -B, -D, -E, -F, -H and -S. The GTFs are 
required for core promoter recognition, promoter opening, transcription start site 
selection, and initial RNA synthesis (Table 2).  
 
Figure 3: Regulatory factors and the basal transcription machinery at the core promoter 
Complexes involved in Pol II transcription initiation and important cis-regulatory elements are depicted (RE 
= regulatory element, TATA = TATA box, INR = Initiator, DPE = downstream promoter element). The 
transcription start site is indicated with an arrow. Gene looping through Mediator-Cohesin interaction is 
indicated. Modular architecture of the coactivator complex Mediator is shown (head = blue,  
middle = green, tail = pink, kinase = orange). Mediator subunits essential for yeast viability are outlined in 
yellow. All proteins and complexes are drawn approximately at relative scale. Image courtesy of T. 
Koschubs, Gene Center. 
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Upon ATP hydrolysis the promoter DNA is melted and the template strand is positioned 
into the active cleft of Pol II (open complex formation) (Wang et al, 1992). With the help 
of TFIIB, the transcription start site (TSS) is recognized and RNA synthesis is intitiated 
(initiation) (Cho & Buratowski, 1999; Pardee et al, 1998; Ranish et al, 1999). When the 
transcript reaches a length of at least seven nucleotides TFIIB is released and Pol II 
enters the elongation phase (promoter clearance) (Pal et al, 2005). Most of the 
initiation factors are left behind in the promoter-bound scaffold complex, which allows 
rapid transcription reinitiation of previously transcribed genes (Yudkovsky et al, 2000). 
 
1.2.2 Elongation and the CTD-code 
The elongating Pol II transcription complex undergoes several transitions accompanied 
by changes in the phosphorylation pattern of the CTD (CTD code). The CTD code 
determines the factors associating with Pol II ensuring cotranscriptional RNA 
processing and chromatin modifications (Buratowski, 2009; Meinhart et al, 2005; 
Phatnani & Greenleaf, 2006; Proudfoot et al, 2002). Upon transcription initiation the 
CTD of Pol II starts getting phosphorylated at Ser5 and Ser7 by the CTD kinases Kin28 
(TFIIH) and Cdk8 (Mediator) facilitating promoter escape (Liu et al, 2004). Shortly after 
transcription initiation, the heterodimeric elongation factor Spt4/5 (DSIF) associates 
with Pol II (Wada et al, 1998). In higher eukaryotes, the negative elongation factor 
(NELF) traps the transcription complex at promoter proximal sites (Yamaguchi et al, 
1999). The capping enzymes are recruited and the nascent mRNA is capped (Wen & 
Shatkin, 1999). The CTD kinase P-TEFb subsequently phosphorylates the C-terminal 
region of Spt5 and the CTD at Ser2 causing a release of the transcription machinery 
and the entry into productive transcript elongation (Kim & Sharp, 2001). In yeast, which 
lacks the mechanism of promoter proximal stalling, all elongation factors are recruited 
in a single 5’ transition approximately 150 nt downstream of the transcription start site 
(Mayer et al, 2010). During elongation, the complex interplay of CTD phosphatases 
and the CTD kinases Ctk1 and Bur1 changes the CTD code from high Ser5/Ser7 
phosphorylation at the 5’ end of the gene to high Ser2 phosphorylation at the 3’ end of 
the gene (Buratowski, 2009).  
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1.2.3 Termination and reinitiation 
When the transcription machinery encounters the poly (A) site at the 3’ end of genes 
the final phase of the transcription cycle is reached and the elongation factors are 
replaced by termination factors (Richard & Manley, 2009). During this phase transcript 
cleavage, polyadenylation and termination occurs. Similar to the preceding phases the 
underlying processes are highly regulated and require a specific set of factors, such as 
Pcf11, Rat1 and Rai1. At protein-coding genes, termination is coupled to RNA 
processing events and often occurs far downstream of the poly (A) site (Buratowski, 
2005; Proudfoot, 1989). The underlying mechanisms are still poorly understood.  
After termination, Pol II is released from the template DNA and can enter facilitated 
reinitiation through association with the promoter bound scaffold complex (Yudkovsky 
et al, 2000). This scaffold complex comprises TFIIA, -D, -E, -H and Mediator, and is 
stabilized by gene-specific activators. The direct recruitment of Pol II into the preformed 
complex was suggested to enable rapid PIC formation and consequently increased 
levels of gene transcription.  
 
 
1.3 Regulation of eukaryotic transcription initiation 
1.3.1 Core promoter elements 
Core promoter elements (CPE) are conserved cis-regulatory DNA motifs required for 
promoter recognition, PIC stability, promoter opening and transcription initiation. In 
eukaryotes, at least seven different CPE have been identified so far (Juven-Gershon et 
al, 2008). CPE are not universally present in all promoters, but occur in different 
combinations thus adding an additional layer of regulation (Müller et al, 2007).  
The evolutionary most ancient CPE, which are found in archaeal and eukaryotic 
promoters, comprise the TATA box, the TFIIB-recognition element (BRE) and the 
initiatior element (INR) (Soppa, 1999). The TATA box was the first described CPE and 
comprises the highly conserved consensus motif TATAWAWR. In most eukaryotes, it 
is located 25-30 bp upstream of the transcription start site (TSS) and marks the 
assembly point for the PIC. In yeast, the distance is more variable (40-120 bp) and 
therefore Pol II has to scan for the TSS after open complex formation (Struhl, 1989). In 
all species, the TATA box binding protein (TBP) binds directly to the TATA box bending 
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the promoter DNA (Kim et al, 1993a; Kim et al, 1993b). The TATA box is flanked up- 
and downstream by BREs, the BREu and BREd, respectively (Deng & Roberts, 2006). 
TFIIB, a GTF directly interacting with TBP and Pol II, contacts these elements further 
stabilizing the PIC and enforcing directionality (Tsai & Sigler, 2000). The INR overlaps 
with the TSS and is sufficient for directing accurate transcription from TATA-less 
promoters through direct interaction with TFIID (Chalkley & Verrijzer, 1999; Smale, 
1997). Interestingly, promoters of trichomonads (a very early-diverging eukaryotic 
lineage) seem to completely lack functional TATA boxes and rely on a highly 
conserved INR instead (Liston & Johnson, 1999).  
Other CPE described in metazoan promoters, like the downstream core promoter 
element (DPE), the motif ten element (MTE) and the downstream core element (DCE), 
are even less understood and further complicate the underlying regulatory mechanisms 
(Juven-Gershon et al, 2008). All efforts to identify CPE, other than the TATA box and a 
degenerate INR, in the well-characterized yeast species Saccharomyces cerevisaea 
(Sc) failed so far. Nevertheless, recent genome-wide studies revealed that TATA boxes 
are found in less than 20% of yeast and metazoan promoters, clearly indicating the 
presence of additional CPE (Basehoar et al, 2004). Identification of these elements 
using bioinformatics might be particularly difficult because they are either very 
degenerate, relying more on biophysical properties than DNA sequence or because 
other determinants like chromatin environment play an important role.  
 
1.3.2 Promoter accessibility and chromatin 
In contrast to the “naked” DNA in bacteria, the genomic DNA in eukaryotes, and to 
some extend in archaea, is bound by histone proteins (Reeve, 2003; Sandman & 
Reeve, 2005). Therefore, most CPE are not readily accessible for binding. In 
eukaryotic cells, a 146 base pair DNA stretch is wrapped around a histone octamer, 
formed by two H2A/H2B and two H3/H4 heterodimers (Luger et al, 1997). The so-
called nucleosomes represent the primary unit of chromatin structure. Chromatin 
serves a dual role within the cell by compacting the genome and by restricting the 
access of DNA-binding factors (Li et al, 2007).  
In bacteria, where DNA is always accessible, the RNAP has an inherent, sigma factor-
directed promoter-binding ability (Mooney et al, 2005). Therefore, binding affinities 
represent the major determinant of promoter strength and regulatory factors merely 
increase the affinity of RNAP.  
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In contrast, eukaryotic DNA is generally inaccessible and Pol II does not have inherent 
promoter binding abilities but relies on a set of positive cofactors, namely chromatin 
remodelers, chromatin modifiers and coactivator complexes, to promote PIC formation 
and transcription intiation (Table 2) (Sikorski & Buratowski, 2009; Thomas & Chiang, 
2006).  
 
Table 2: Factors involved in Pol II transcription initiation  
adapted from (Sikorski & Buratowski, 2009; Thomas & Chiang, 2006) 
 
 
Based on recent genome-wide nucleosome occupancy studies, promoters in 
eukaryotes can be classified into two contrasting categories, “open” and “covered”, 
comprising constitutive and highly regulated genes, respectively (Cairns, 2009; Field et 
al, 2008; Tirosh & Barkai, 2008). Computational analysis and predictions of 
nucleosome positions revealed that promoter accessibility is highly dependent on 
biophysical properties, like DNA curvature or stiffness (Segal & Widom, 2009; Struhl, 
1985). Open promoters contain an approximately 150 bp nucleosome-depleted region 
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directly upstream of the TSS enabling direct access for transcription factor binding. A 
combination of two sequence elements into a tripartite structure stabilizes this open 
architecture: a central poly(dA:dT) tract flanked by nucleosome positioning sequences, 
fixing the so-called -1 and +1 nucleosome in place (Segal et al, 2006; Struhl, 1985; 
Yuan et al, 2005). Interestingly, most of the open promoters lack a functional TATA box 
and contain the H2A variant H2A.Z (htz1 in yeast) at the +1 or -1 nucleosome (Raisner 
et al, 2005; Zhang et al, 2005). In contrast, in covered promoters TATA boxes are more 
enriched, but all CPE and most of the other cis-regulatory elements are masked 
through nucleosome binding (Basehoar et al, 2004; Huisinga & Pugh, 2004). Often a 
single transcription factor binding site is exposed, which is bound upon activation by a 
“pioneering” transcription factor (Cairns, 2009). Subsequent recruitment of chromatin 
remodelers and modifiers makes the core promoter accessible and enables recruitment 
of coactivator complexes facilitating PIC formation (Becker & Hörz, 2002; Sikorski & 
Buratowski, 2009). Therefore, chromatin structure and consequently chromatin 
remodeling represents an important additional layer of regulation in eukaryotic gene 
regulation.  
 
1.3.3 Positive cofactors 
Positive cofactors are typically subdivided based on their mechanism of facilitating 
Pol II transcription initiation into two classes, namely coactivators and chromatin 
remodelers/modifiers (Sikorski & Buratowski, 2009; Thomas & Chiang, 2006). 
However, many complexes have multiple roles making a clear classification difficult.  
Multiprotein coactivator complexes, such as the Mediator complex (Malik & Roeder, 
2010), the Spt-Ada-Gcn5-acetyltransferase complex (SAGA) (Rodríguez-Navarro, 
2009) and the basal transcription factor TFIID (Cler et al, 2009), are highly conserved 
from yeast to man. Gene specific activators recruit these coactivators to the core 
promoter, where they facilitate and stabilize PIC formation through multiple contacts 
with the basal transcription machinery (Sikorski & Buratowski, 2009). Whereas 
Mediator is considered a general coactivator complex required for transcription of most 
Pol II genes (see Chapter 1.4) (Kornberg, 2005), the role of SAGA and TFIID seems to 
be partially redundant (Basehoar et al, 2004; Huisinga & Pugh, 2004; Lee et al, 2000). 
While some activators, like the acidic activators Gal4 and Gcn4 target both complexes 
(Reeves & Hahn, 2005), other activators, like Rap1 seem to recruit only TFIID (Mencía 
et al, 2002). Recent genome-wide chromatin immunoprecipitation (ChIP) studies in 
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yeast revealed that highly regulated TATA-containing genes rely more on SAGA while 
constitutive TATA-less genes rely more on TFIID (Basehoar et al, 2004; Huisinga & 
Pugh, 2004). This is in accordance with previous observations in higher eukaryotes, 
where TFIID was shown to recognize and bind directly to the INR, not requiring a 
functional TATA box for transcription activation (Chalkley & Verrijzer, 1999). Taken 
together, several modes of promoter recognition and PIC formation seem to exist, 
which are determined by activator-coactivator and CPE-coactivator interactions 
(Bhaumik, 2011; Sikorski & Buratowski, 2009).  
SAGA and TFIID appear similar in shape and share several TBP-associated factors 
(TAFs). Interestingly, many TAFs contain a conserved histone fold domain and form 
heterodimeric subcomplexes. These heterodimers appear to be a common building 
block important for the architecture and function of both complexes (Cler et al, 2009; 
Leurent et al, 2002). Nevertheless, the two complexes differ in several key features, 
which helps to explain their mechanistic specificity. The multisubunit TFIID comprises 
the TATA-binding protein (TBP) and 13-14 different TAFs, some of which appear to be 
present in at least two copies (Cler et al, 2009). The TFIID-specific subcomplex 
Taf1/Taf2 was shown to recognize and bind the INR (Kaufmann & Smale, 1994). In 
addition, the TFIID-specific subunit Taf3 interacts through a plant homeodomain (PHD) 
finger with trimethylated histone H3 at lysine 4 (H3K4me3) facilitating recruitment of 
TFIID. The recruitment is further stimulated by acetylation of H3 at lysine 9 (H3K9) and 
lysine 14 (H3K14) (Taverna et al, 2007).  
The multiprotein complex SAGA comprises 21 subunits in yeast. Only the 5 TAFs 
shared with TFIID and the ATM/PI-3-kinase Tra1 shared with NuA4 complex are 
essential for yeast viability (Bhaumik, 2011; Rodríguez-Navarro, 2009). In contrast to 
TFIID, TBP is not a stable subunit of SAGA, but interacts transiently with the SAGA-
specific subunit Spt3 during transcription activation (Mohibullah & Hahn, 2008). The 
two SAGA-specific subunits Gcn5 and Ubp8 possess histone acetyltransferase and 
deubiquitylase activities, respectively. Both subunits were shown to regulate gene 
expression of a subset of genes through modulation of the chromatin structure (Henry 
et al, 2003).  
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1.3.4 Negative cofactors 
In addition to the plethora of positive cofactors, three negative cofactors have been 
described in yeast so far (Sikorski & Buratowski, 2009). The Ssn6-Tup1 complex is 
considered a global repressor complex, antagonizing transcriptional activation through 
repressive nucleosome positioning, histone deacetylation and interference with Mediator 
function (Zhang & Reese, 2004). Interestingly, the other two negative cofactors, Mot1 and 
the heterodimeric NC2 complex, were identified in an extragenic suppressor screen of a 
temperature-sensitive Mediator mutation (Gadbois et al, 1997; Lee et al, 1998). Mutations 
in these factors compensate the loss of Mediator function at elevated temperatures. Both 
cofactors act very specifically through direct interactions with TBP. Mot1, a Snf2 ATPase, 
removes TBP from the promoter, whereas NC2 blocks TBP-TFIIA and TBP-TFIIB 
interactions (Auble, 2009; Pereira et al, 2003). While the mode of action is very different, 
the outcome of interfering with PIC formation and stability is the same. Interestingly, recent 
genome-wide ChIP studies found NC2 and Mot1 at many active yeast promoters (van 
Werven et al, 2008). While NC2 and Mot1 repress TATA box containing promoters, they 
seem to activate TATA-less promoters. Although the underlying mechanism is still unclear, 
it was suggested that Mot1 and NC2 might remove non-functional TBP from the promoter 
to enable binding of other factors (Sikorski & Buratowski, 2009).  
 
 
1.4 The general coactivator complex Mediator 
1.4.1 Discovery and conservation 
First evidence for the existence of Mediator came from squelching experiments in yeast 
(Gill & Ptashne, 1988) and mammalian cells (Triezenberg et al, 1988). Overexpression 
of one activator interfered with the activation of Pol II transcription by another activator. 
At the beginning the effect was attributed to competitive binding to the same target 
within the basal transcription machinery. However, addition of an excess of Pol II or 
any GTF to a crude yeast in vitro transcription system did not relieve the squelching 
effect, while addition of a crude yeast extract did (Flanagan et al, 1991; Kelleher et al, 
1990). This strongly indicated the existence of an intermediate layer of regulation 
between the activators and the transcription machinery in eukaryotes. The unknown 
factor was termed Mediator, but it took another four years until the Mediator complex 
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was first purified and characterized (Kim et al, 1994). In parallel, genetic screens in 
yeast had identified several suppressors of the cold-sensitve phenotype of a Pol II CTD 
truncation. The identified extragenic suppressors were termed suppressors of RNA 
polymerase B (Srb) (Nonet & Young, 1989). Later on, all 9 Srb proteins turned out to 
be subunits of the large coactivator complex Mediator.  
Mediator was subsequently purified from various fungi, metazoans and a plant 
(Bäckström et al, 2007; Boube et al, 2002). Comparative genomics identified an 
ancient 17-subunit core Mediator, which is conserved in all eukaryotes (Bourbon, 2008) 
(Table 3).  
 
Table 3: Mediator subunit composition and modular architecture  
a Subunits comprising the ancient core Mediator are shown in red (Bourbon, 2008); subunits that are 
essential for yeast viability are shown are underlined. 
b pdb code is given when structural information on individual subunits or subcomplexes is available  
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1.4.2 Modular architecture and structure 
Based on electron microscopy (Asturias et al, 1999; Davis et al, 2002; Dotson et al, 
2000), biochemical studies (Kang et al, 2001) and gene expression profiling (van de 
Peppel et al, 2005), Mediator subunits were suggested to reside in four flexibly linked 
modules, the head, middle, tail and the dissociable kinase modules (Figure 3). The 
modular architecture as well as the subunit composition appears to be conserved from 
yeast to man (Table 3).  
The Sc Mediator complex has a molecular weight of around 1.4 MDa and comprises 25 
subunits, which have all homologues in higher eukaryotes (Bourbon, 2008). 10 
subunits, which are all part of the core Mediator, are essential for cell viability (Table 3) 
(Myers & Kornberg, 2000). Many of the subunit-subunit interactions within Mediator are 
known from a large-scale yeast two-hybrid screen (Guglielmi et al, 2004) and 
biochemical studies (Baumli et al, 2005; Beve et al, 2005; Koschubs et al, 2010; 
Larivière et al, 2006; Takagi et al, 2006). Structural information on Mediator subunits is 
available for CycC (Hoeppner et al, 2005), Med7C/21 (Baumli et al, 2005), Med7N/31 
(Koschubs et al, 2009), Med8C/18/20 (Larivière et al, 2006), Med15 (Thakur et al, 
2008; Yang et al, 2006) and Med25 (Bontems et al, 2010) (Table 3). The architecture 
of the Mediator head (Takagi et al, 2006) and middle module (Baumli et al, 2005; 
Koschubs et al, 2010) is well established through recombinant coexpression and 
copurification studies. The two modules were suggested to interact through the head 
module subunit Med6 and the middle module subcomplex Med7C/21 (Baumli et al, 
2005). Numerous low resolution electron microscopic reconstructions of the complete 
Mediator from various species revealed the highly flexible nature of the complex and 
large conformational changes in response to activator binding (Asturias et al, 1999; Cai 
et al, 2009; Cai et al, 2010; Davis et al, 2002; Dotson et al, 2000; Elmlund et al, 2006; 
Näär et al, 2002; Taatjes et al, 2002; Taatjes et al, 2004).  
 
1.4.3 Mediator function in transcriptional regulation 
Mediator function is best described as integrating signals from various regulatory 
proteins and transferring a calibrated output to the basal transcription machinery 
(Bjorklund & Gustafsson, 2005; Kornberg, 2005; Malik & Roeder, 2010; Naar et al, 
2001). Mediator interacts with many medically important human transcription 
regulators, including hormone receptors (Taatjes et al, 2004), vitamin D receptor 
(Taatjes et al, 2004) and p53 (Meyer et al, 2010). Recent studies have linked Mediator 
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to various human diseases, like Alzheimer disease (Xu et al, 2011), congenital 
malformations (Muncke et al, 2003), mental retardation (Philibert & Madan, 2007) and 
cancer (Firestein et al, 2008; Morris et al, 2008; Zhu et al, 1999). In yeast, Mediator is 
globally required for Pol II transcription (Holstege et al, 1998). Mediator is thought to 
act by promoting transcription initiation complex assembly through activator-Mediator, 
Mediator-Pol II and Mediator-GTF contacts (Cantin et al, 2003). Mediator is recruited to 
the promoter by activators independent of Pol II recruitment (Cosma et al, 2001) and 
remains in the scaffold complex after initiation to enable rapid reinitiation of previously 
transcribed genes (Yudkovsky et al, 2000). A recent study has demonstrated a direct 
interaction between Mediator and cohesin at promoters in embryonic stem cells (Kagey 
et al, 2010). This interaction promotes gene looping and thus physically connects 
distant enhancer elements with the core promoter. The dissociable Mediator kinase 
module, comprising the Cdk8 kinase, CycC, Med12 and Med13, phophorylates the 
CTD at Ser5 together with Kin28 (TFIIH) and consequently facilitates transcription 
initiation and promoter escape (Liu et al, 2004).  
Global gene expression studies of Mediator deletion mutants have implicated the 
different modules in the regulation of different subsets of genes (Beve et al, 2005; 
Holstege et al, 1998; Singh et al, 2006; van de Peppel et al, 2005). The middle module 
is required for regulating HSP genes and low-iron response genes, the tail module for 
regulating HSP and OXPHOS genes, and the kinase module for regulating genes 
required during nutrient starvation.  
 
1.4.4 Head module architecture and function 
The Sc head module comprises five essential subunits (Med6, Med8, Med11, Med17, 
and Med22) and two non-essential subunits (Med18 and Med20) (Table 3). The head 
module architecture was characterized in detail by yeast-two-hybrid screens (Esnault et 
al, 2008; Guglielmi et al, 2004) as well as coexpression and copurification studies 
(Baumli et al, 2005; Larivière et al, 2006; Takagi et al, 2006). Med6, Med8, Med11 and 
Med22 interact directly with the central scaffolding subunit Med17, while the dimeric 
Med18/20 subcomplex interacts with the C-terminus of Med8 (Med8C). Structural 
information is only available for this non-essential Med8C/18/20 subcomplex (Larivière 
et al, 2006).  
The Mediator head module plays an important role during PIC assembly, contacting 
Pol II-TFIIF (Takagi et al, 2006), Pol II CTD (Kang et al, 2001; Näär et al, 2002), TATA-
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binding protein (TBP) (Kang et al, 2001; Larivière et al, 2006), TFIIB (Kang et al, 2001) 
and TFIIH (Esnault et al, 2008). A temperature-sensitive mutation in Med17 (med17-ts; 
srb4-138 strain) affecting head module integrity abolishes the stimulation of basal 
transcription in vitro (Ranish et al, 1999; Takagi et al, 2006), prevent association of Pol 
II and GTF with core promoters in vivo (Bhaumik et al, 2004) and cause a global 
shutdown of mRNA synthesis (Holstege et al, 1998; Thompson & Young, 1995). Sc 
Med11 and Med22 are important for head module architecture and function. They both 
bind and stabilize the central head subunit Med17 (Kang et al, 2001; Takagi et al, 
2006). A temperature-sensitive mutation in Med22 (srb6-107) causes similarly to 
med17-ts a global decrease in mRNA synthesis (Thompson & Young, 1995). Single 
point mutations in Med22 can act as extragenic suppressors of the med17-ts 
phenotype (Lee et al, 1998), of the cold-sensitive phenotype of Rpb1 CTD truncation 
(Thompson et al, 1993), and of the lethal CTD Ser2 phosphorylation site substitution 
mutation (Yuryev & Corden, 1996). Med11 was shown to directly interact with the Rad3 
subunit of TFIIH in yeast-two-hybrid assays and a point mutation in Med11 reduced 
promoter occupancy of TFIIH kinase module (TFIIK) and consequently CTD Ser5 
phosphorylation in vivo (Esnault et al, 2008). Despite the important role of Mediator 
head during transcription inititiation, the underlying molecular mechanisms as well as 
the functions of individual subcomplexes are still unclear.  
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1.5 Aims and scope of this work 
The general coactivator complex Mediator constitutes the central interface between 
activators and Pol II, enabling regulated transcription of most if not all protein-coding 
genes (Kornberg, 2005; Malik & Roeder, 2010). Despite its fundamental role in gene 
regulation, its three-dimensional structure and biochemical function are still poorly 
understood. The low abundance of Mediator in cells and its complex architecture made 
X-ray structure determination and high-resolution electron microscopy using natively 
purified complexes so far impossible. Nevertheless, only by correlating observed 
molecular interactions with functional roles in vitro and in vivo, the Mediator mechanism 
can be elucidated on a molecular level. 
This study focused on the 7-subunit Mediator head module, which plays a pivotal role 
during transcription initiation. Conditional mutations in the head module abolish 
association of Pol II and the GTF with promoters in vivo (Bhaumik et al, 2004) and 
consequently cause a global shutdown of Pol II transcription (Holstege et al, 1998; 
Thompson & Young, 1995). Furthermore, several direct interactions with PIC 
components, namely Pol II-TFIIF (Takagi et al, 2006), Pol II-CTD (Kang et al, 2001; 
Näär et al, 2002), TATA-binding protein (TBP) (Kang et al, 2001; Larivière et al, 2006), 
TFIIB (Kang et al, 2001) and TFIIH (Esnault et al, 2008), had been described. Despite 
the importance of Mediator head, high-resolution structural information was only 
available for the non-essential Med8C/18/20 subcomplex. Therefore, a structure-
function-system correlation, combining X-ray crystallography, yeast genetics, 
biochemical assays, chromatin immunoprecipitation, genome-wide expression profiling 
and label-free mass spectrometry, was used in this study to elucidate the submodular 
architecture and molecular mechanisms underlying Mediator head module function. In 
addition, in vitro transcription and PIC assembly assays using native yeast promoter 
templates, nuclear extracts and the corresponding yeast activator were established and 
optimized. These assays allow functional studies of Pol II transcription initiation in an in 
vivo like environment with the advantage of in vitro manipulations, like depletion and 
addition of recombinant factors. During the first main project, the function of the non-
essential Med8C/18/20 subcomplex was characterized in detail and correlated with 
structural data already available in the lab (Larivière et al, 2006). In the second main 
project, the essential Med11/22 subcomplex, which interacts directly with TFIIH 
(Esnault et al, 2008), was structurally and functionally characterized.  
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1.6 Additional contributions 
Additional experimental results leading to co-author publications are listed below. A 
more detailed description of the respective contributions is given in Chapter 3.4.  
The Mediator middle submodule Med7N/31 was functionally characterized (Chapter 
3.4.2). In vitro transcription with yeast nuclear extracts revealed a Med7N/31 
requirement for activation of Pol II transcription by acidic activators. Furthermore, a 
cooperation of Med31 and TFIIS during transcription initiation was established 
(Koschubs et al, 2009).  
The functional interaction of the metazoan Mediator subunit Med25 with the 
archetypical acidic transcription factor VP16 was analyzed (Chapter 3.4.3). An in vitro 
quenching assay was established to identify surface residues important for the Med25-
VP16 interaction. Additionally, the individual contributions of VP16 subdomains and the 
underlying cooperativity during transcription activation in yeast were characterized. The 
results contribute to the understanding of how activation domains have evolved to 
adapt to different unrelated target surfaces (Vojnic et al., in press).  
The functional role of TFIIB during scanning and transcription start site selection was 
analyzed (Chapter 3.4.4). In vitro assays with modified promoter templates were 
established to test mutations on the protein as well as on the DNA side. We could 
demonstrate that the INR alone determines TSS selection and that the -8 position is 
important for TSS recognition. Furthermore, our results suggest that the INR is 
recognized with the help of the TFIIB B-reader element during Pol II scanning 
(Kostrewa et al, 2009).  
Furthermore, in vitro assays using yeast nuclear extracts were established to study the 
function of Iwr1 (Czeko et al., in press) and the Prp19 complex (Chanarat et al., 
manuscript in revision) during transcription. All results and experimental details are 
described in detail in the PhD thesis of the respective first author and the respective 
publication.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Strains 
 
Table 4: Yeast strains (Sc) 
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Table 5: Yeast strains (Sp) 
 
Table 6: E. coli strains 
 
 
2.1.2 Plasmids 
 
Table 7: Plasmids used for recombinant expression of Med11/22 in E. coli 
table continued on next page 
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table continued on next page 
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Table 8: Plasmids used for recombinant expression of other proteins in E. coli  
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Table 9: Plasmids used as templates for yeast complementation experiments 
table continued on next page 
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table continued on next page 
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Table 10: Plasmids used for in vitro assays 
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2.1.3 Oligonucleotides 
A detailed list with all oligonucleotide used for molecular cloning is available through 
the Cramer laboratory. 
 
Table 11: Oligonucleotides used for in vitro experiments 
 
Table 12: Oligonucleotides used for quantitative real-time PCR 
 
MATERIALS AND METHODS 
26 
 
2.1.4 Antibodies 
 
Table 13: Antibodies used in this study 
 
2.1.5 Growth media and additives 
 
Table 14: Growth media 
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Table 15: Growth media additives 
 
2.1.6 Buffers and solutions 
Standard buffers and solutions were prepared as described (Sambrook & Russell, 
2001). 
 
Table 16: General buffers and solutions 
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Table 17: Recombinant protein purification buffers 
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Table 18: Buffers for in vitro biochemical assays 
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Table #: PCR program 
2.2 Methods 
2.2.1 Molecular cloning 
Preparation of chemically competent E. coli  
200 ml LB medium were inoculated with an overnight culture of the desired E. coli strain 
(Table 6) to a starting OD600 of 0.05. Cells were grown at 37°C to an OD600 of 0.5, then 
incubated on ice for 10 minutes. All following steps were carried out at 4°C. Cells were 
pelleted by centrifugation (3000 g / 10 min / 4°C) and washed with 50 ml TFB-1. Cells were 
again pelleted by centrifugation (3000 g / 10 min / 4°C) and resuspended in 4 ml of TFB-2. 
Cell suspension was aliquoted into tubes on dry ice and subsequently stored at – 80°C. 
 
Polymerase chain reaction (PCR) 
PCR primers usually contained a 5’ overhang (5’-GGGCCCGGG-3’) followed by the 
desired restriction site and 20-25 nt complementary to the target sequence. 
Hexahistidine (6His) tags and thrombin cleavage sites were introduced either by in-
frame cloning into the respective expression vector or by PCR. Bicistronic expression 
constructs were generated as described (Larivière et al, 2006). PCR reactions were 
carried out with Taq polymerase (Fermentas), Herculase or Herculase II polymerases 
(Stratagene), Pwo SuperYield DNA Polymerase (Roche) or Phusion High-Fidelity DNA 
Polymerase (Finnzymes) depending on the requirements and according to the 
manufacturerʼs manual. 50 µl PCR reactions typically contained 1-50 ng plasmid template 
or 100-500 ng yeast genomic DNA. Thermocycling programs usually comprised 30 cycles 
and were done on the Biometra T3000 Thermocycler. Annealing temperature and 
elongation times were adjusted to the specific needs of the individual reactions. PCR 
products were visualized by agarose gel electrophoresis (1-2% w/v agarose, 1:10000 
SYBR Safe DNA gel stain (Invitrogen) and 1x TBE buffer).  
 
Mutagenesis 
Point mutations and deletions were introduced using the PCR overlap extension 
method (Higuchi et al, 1988). Forward and reverse mutagenesis primers were 
designed carrying the mutation flanked by 20-25 nt complementary sequence on both 
sides. First two standard PCR reactions were done, amplifying the 5’ and 3’ end of the 
gene with an overlapping region containing the desired mutation. In a second step the 
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two overlapping fragments were used as templates to amplify the whole gene carrying 
the newly introduced mutation.  
 
Restriction digest, dephosphorylation and ligation 
PCR products were purified using the QIAquick PCR purification kit (Qiagen). Vectors 
and purified PCR product were typically digested over night using restriction 
endonucleases (New England Biolabs and Fermentas) according to the manufacturer’s 
manual. Digested vectors were subsequently dephosphorylated by addition of 1 u 
FastAP enzyme (Fermentas) according to the manufacturer’s manual. Typically, DNA 
fragments were separated by agarose gel electrophoresis (1-2% w/v agarose, 1:10000 
SYBR Safe DNA gel stain (Invitrogen) and 1x TBE buffer) and extracted using the 
QIAquick Gel Extraction Kit (Qiagen). PCR products and linearized vectors were 
typically ligated overnight at 16°C using 5 u of T4 DNA ligase (Fermentas) in a 20 µl 
reaction. A 5- to 10-fold molar excess of insert relative to the linearized vector was 
used.  
 
Transformation in E. coli and plasmid preparation 
Chemically competent E. coli XL-1 blue cells were transformed with DNA using a heat 
shock protocol. A 50 µl aliquot of cells was thawed on ice and either 5 µl of a ligation 
reaction or 1 µl of plasmid were added. After 15 min of incubation on ice, a heat shock 
was applied (45 sec / 42°C) followed by 2-5 min incubation on ice. 200 µl of LB 
medium were added and cells were incubated at for 1 h at 37°C shaking vigorously. 
Afterwards, cells were plated on LB-agar plates containing the corresponding 
antibiotics for selection of transformed cells and incubated over night at 37°C. A single 
colony was used to inoculate 5 ml LB-medium containing the corresponding antibiotics. 
The culture was grown over night at 37°C and plasmids were isolated using the 
QIAprep Spin MiniPrep kit (Qiagen). Newly generated plasmids were verified by 
restriction digest and DNA sequencing (Eurofins or GATC). 
 
2.2.2 General protein methods 
Protein expression and selenomethionine labeling  
Proteins were recombinantly expressed in E. coli BL21-Codon Plus (DE3)-RIL cells 
transformed with the respective expression plasmids as described previously (see 
2.2.1). LB medium, containing the corresponding antibiotics, was inoculated with a pre-
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culture to a starting OD600 of 0.1. Cultures were grown to an OD600 of 0.5-0.8 (37°C / 
140 rpm), then cooled down on ice for 30 min. Protein expression was induced by 
addition of 0.5 mM IPTG and incubation over night (18°C / 140 rpm). Cells were 
harvested by centrifugation (4400 g / 15 min / 4°C / Sorvall SLC6000 rotor). Cell pellets 
were flash-frozen in liquid N2 and stored at -80°C.  
Selenomethionine labeling of proteins was essentially done as described (Budisa et al, 
1995). Proteins were recombinantly expressed in methionine auxotroph E. coli Rosetta 
B834 (DE3) cells. LB medium, containing the corresponding antibiotics, was inoculated 
with a pre-culture to a starting OD600 of 0.1. Cultures were grown to an OD600 of 0.6 
(37°C / 140 rpm). Cells were then harvested (4400 g / 15 min / 4°C / Sorvall SLC6000 
rotor), washed and resuspended in minimal medium containing 50 mg/l 
selenomethionine and the corresponding antibiotics. Cultures were grown to OD600 0.8 
(37°C / 140 rpm) in the minimal medium. After cooling the culture down, protein 
expression was induced by addition of 0.5 mM IPTG and incubation over night (18°C / 
140 rpm). Cells were harvested by centrifugation (4400 g / 15 min / 4°C / Sorvall 
SLC6000 rotor). Cell pellets were flash-frozen in liquid N2 and stored at -80°C.  
 
Cell lysis 
Cell pellets were thawed on ice and then resuspended in the appropriate lysis buffer 
containing protease inhibitor cocktail. Cells were disrupted on ice by sonication (12 min 
/ 25% duty cycle / 30-40 output value). Afterwards the lysate was cleared by 
centrifugation (max. speed / 30 min / 4°C / Sorvall SS34 rotor). 
 
Protein purification 
Typically, recombinant proteins were purified using an initial affinity column followed by 
an ion exchange column and a size exclusion column. The specific purification 
protocols vary for each protein/subcomplex (see Chapter 2.2.3.). 
 
Protein concentration 
Purified proteins were concentrated using “Amicon Ultra” spin concentrators (Millipore) 
with appropriate sample volume and molecular weight cut-off. The manufacturer’s 
manual was followed.  
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Protein concentration determination 
Protein concentration was usually determined by the Bradford assay (Bradford, 1976). 
The assay was performed according to the manufacturer’s manual (Bio-Rad). A 
standard curve was generated for each batch of dye reagent using serum bovine 
albumin (Roth). Alternatively, protein concentrations were calculated from the 
absorbance at 280 nm measured with a NanoDrop spectrophotometer. Absorption 
coefficients were calculated using ProtParam (http://expasy.org/tools/protparam.html). 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were analyzed by SDS-PAGE (Laemmli, 1970) with 15-17 % 
acrylamide gels (acrylamide:bisacrylamide ratio = 37.5:1) in the Bio-Rad gel systems. 
Buffers and gel solutions are listed in Table 16. Before loading, SDS sample buffer was 
added and samples boiled for 2 min at 95°C. Samples requiring high resolution over a 
broad molecular weight range, like Mediator complex purifications and immobilized 
template assay elutions, were separated using pre-casted NuPAGE Novex Bis-Tris 
minigels (Invitrogen). MOPS and MES running buffers (Invitrogen) were used 
according to the manufacturer’s manual.  
Gels were stained with Coomassie gel staining solution for approximately1 h and 
subsequently destained with destaining solution over night. Alternatively, gels were 
used for Western blotting as described below.  
 
Western Blot 
Proteins were first separated by SDS-PAGE as described above and then transferred 
to a PVDF membrane (Schleicher & Schuell; pre-wet with 100% ethanol) using the wet 
blotting system from Bio-Rad. The manufacturer’s manual was followed. Transfer was 
done either at 100 V for 1 h on ice or at 35 V over night at 4°C. For pre-cast NuPAGE 
Novex Bis-Tris minigels (Invitrogen) the recommended NuPAGE transfer buffer 
containing 20% (v/v) ethanol was used. After transfer, the membranes were air-dried 
for 30 min and then blocked for at least 1 h with WB blocking buffer. The blot was then 
incubated for at least 3 h at room temperature with the primary antibody in WB blocking 
buffer followed by three washing steps with WB blocking buffer, incubating 10 min at 
each step. Afterwards, the membrane was incubated with the secondary antibody in 
WB blocking buffer for at least 1.5 h. The membrane was washed three times with 1x 
PBS, incubating 10 min at each step. Secondary antibodies were usually coupled to 
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horseradish peroxidase. Signals were detected using the chemiluminescence kit 
(Pierce) followed by exposure of the membrane to high-sensitivity films (Invitrogen) and 
subsequent developing using a X-omat M35 developing machine (Kodak). Alternatively 
the chemiluminscent signals were detected with the Mini-LAS300 System (Fujifilm Life 
Sciences) and quantified using the ImageQuant software suite (GE Healthcare).  
 
Edman sequencing 
Proteins were separated by SDS-PAGE, stained and destained as described above. 
The band of interest was excised, dried in a speed-vac and subsequently rehydrated in 
50 µl swelling buffer. Afterwards 200 µl of ddH2O and a small piece of PVDF 
membrane (Schleicher & Schuell), pre-wet with 100% methanol, were added. Once the 
solution turned blue, 20 µl of methanol were added. The sample was incubated 
approximately2 days at room temperature. Then the membrane piece was washed 5x 
with 10% (v/v) methanol by incubating for 1 min each time. Afterwards, the protein was 
N-terminally sequenced from the dry membrane using a PROCISE 491 sequencer 
(Applied Biosystems).  
 
Mass spectrometry 
Proteins were separated by SDS-PAGE, stained and destained as described above. 
For protein identification by mass spectrometry, the band of interest was excised, 
transferred to a tube containing 100 µl ddH2O and sent to the protein analysis core 
facility (Adolf-Butenandt-Institute, LMU). Analysis of immobilized template eluates by 
mass spectrometry was performed in collaboration with Dr. Ignasi Forné (Group of 
Prof. Axel Imhof, LMU, Munich) as described in Chapter 2.2.4.  
 
Limited proteolysis 
Limited proteolysis was typically done using chymotrypsin or trypsin proteases (Sigma). 
Usually, 20 µg of purified protein in the respective gelfiltration buffer were incubated 
with 100 ng of protease. Time courses were done by incubating the reactions at 37°C 
for 30 sec, 1 min, 3 min, 10 min, 30 min, and 60 min immediately followed by addition 
of SDS sample buffer and boiling for 2 min at 95°C. Fragments were separated by 
SDS-PAGE and identified by Edman sequencing as described above. 
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Static light scattering 
Static light scattering measurements were done with a triple detector TDA (Viscotek) 
connected to a Superose-6 gelfiltration column (GE Healthcare) preequilibrated with 
corresponding buffer. 200 µl of protein (approximately2 mg/ml) were injected on the 
column and the eluate analysed by the triple detector, recording refractive index, UV 
and viscosity. From these values the hydrodynamic radius and the molecular weight 
were calculated using the static light scattering software package (Viscotek).  
 
Crystallization and structure solution 
Initial crystallization screens were performed at the MPI crystallization facility (MPI of 
Biochemistry, Martinsried). Typically, six different 96-well crystallization screens 
(Hampton Index, Nextal Classics, Nextal - The Cations, Nextal – The Anions, MPI 
Magic I and MPI Magic II) with 200 nl drop size were set up at room temperature by a 
robot. Fine screens around promising conditions were done manually in 24-well 
hanging drop plates (Easy Xtal Tool, Qiagen). Usually pH, protein concentration, 
precipitant and additive concentration was varied. Crystallization drops were set up in 
different protein:buffer ratios (1:1, 1:2 and 2:1) for each condition.  
Crystals of Schizosaccharomyces pombe (Sp) Med18 and of the Sp Med8C/18 
heterodimer were grown at 20°C in hanging drops over reservoirs containing 100 mM 
Tris (pH 8.5), 2 M sodium acetate, and 2 M sodium formate. The Med18 structure was 
solved by the single-wavelength anomalous dispersion method using selenomethionine 
labeled protein crystals. The Med8C/Med18 structure was solved by molecular 
replacement using the Med18 structure as a model . 
Crystals of Med11/22 were grown at 20°C in hanging drops over reservoirs containing 
100 mM MES pH 6, 5.5% PEG 6000 and 100 mM MgCl2. Microseeding was performed 
to optimize crystals. Initial crystals were transferred into 100 µl reservoir solution and 
vortexed vigorously. 0.2 µl of the resulting microseeding solution was added to each 
2 µl drop to nucleate crystal growth. Optimized crystals were harvested by gradually 
adding glycerol to a final concentration of 34% (v/v) and were subsequently flash-
frozen in liquid nitrogen. Diffraction data was collected at 100 K on a PILATUS 6M 
detector at the Swiss Light Source SLS, Villigen, Switzerland. Diffraction data was 
processed using XDS and XSCALE (Kabsch, 1993). The program SOLVE (Terwilliger 
& Berendzen, 1999) identified 36 selenium sites in the asymmetric unit that were used 
for phasing. Solvent flattening, non-crystallographic symmetry averaging and initial 
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model building was done with RESOLVE (Terwilliger & Berendzen, 1999) and 
ARP/warp (Perrakis et al, 2001). The resulting electron density map allowed for manual 
building of most of Med11 and Med22 using COOT (Emsley & Cowtan, 2004). The 
model was refined using conjugate gradient minimization in PHENIX (McCoy et al, 
2007). The asymmetric unit contained twelve Med11/22 heterodimers that deviated 
only slightly at the C-termini of the proteins. The structures and diffraction data have 
been deposited in the Protein Data Bank. All structure figures depict chain A/B and 
were prepared using PyMol (DeLano, 2002) . 
 
2.2.3 Recombinant protein purification protocols 
Purification protocols for all recombinant proteins used in this study are listed below. All 
buffers are listed in Table 17. 
 
Med8C/18/20 and Med18/20 (Sc) 
The cleared lysate from two liters of culture was gradually precipitated by slowly adding 
saturated (NH4)2SO4 solution to a final concentration of 30%. Afterwards, suspension 
was stirred on ice for 30 min and centrifuged (15000 rpm / 30 min / 4°C / Sorvall SS34 
rotor). Supernatant was discarded and the pellet resuspended in 8 ml of buffer A. 
Buffer B was added to a final conductivity of 10-15 mS/cm. The proteins were further 
purified by anion exchange chromatography using a MonoQ 10/100 column  
(GE Healthcare). The column was equilibrated with buffer B containing 100 mM NaCl 
and the complex was eluted with a linear gradient of 20 CVs from 100 mM to 500 mM 
NaCl in buffer B. Subsequently, the sample was applied to a Superdex 200 size 
exclusion column (GE Healthcare) equilibrated with buffer A. The protein was 
concentrated to approximately1 mg/ml, flash frozen in small aliquots in liquid N2 and 
stored at -80°C. 
 
Med8C/18 (Sp) 
The cleared lysate from three liters of culture was loaded onto a 2 ml Ni-NTA column 
(Qiagen) equilibrated with buffer A. The column was washed with 10 CV of buffer A 
containing 10 mM imidazole and with 10 CV of buffer A containing 20 mM imidazole. 
The complex was eluted with buffer A containing 300 mM imidazole. Buffer B was 
added to a final conductivity of 10-15 mS/cm. The proteins were further purified by 
anion exchange chromatography using a MonoQ 10/100 column (GE Healthcare). The 
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column was equilibrated with buffer B containing 100 mM NaCl and the complex was 
eluted with a linear gradient of 10 CVs from 100 mM to 1 M NaCl in buffer B. After 
concentration the sample was applied to a Superose-12 size exclusion column (GE 
Healthcare) equilibrated with buffer A. The protein was concentrated to 
approximately40 mg/ml for crystallization. 
 
Med11/22 (Sc) 
The cleared lysate from three liters of culture was loaded onto a 2 ml Ni-NTA column 
(Qiagen) equilibrated with buffer A. The column was washed with 10 CV of buffer A 
containing 10 mM imidazole and with 10 CV of buffer A containing 20 mM imidazole. 
The complex was eluted with buffer A containing 300 mM imidazole followed by 
overnight cleavage with thrombin while dialyzing against buffer B. The proteins were 
further purified by anion exchange chromatography using a HiTrap Q HP column (GE 
Healthcare). The column was equilibrated with buffer B and the complex was eluted 
with a linear gradient of 25 CVs from 50 mM to 500 mM NaCl in buffer B. 
Subsequently, the sample was applied to a HiLoad Superdex-75 pg 26/60 size 
exclusion column (GE Healthcare) equilibrated with buffer A. 
 
Med25-ACID (Hs) 
The cleared lysate from four liters of culture was loaded twice onto a 2 ml Ni-NTA 
column (Qiagen) equilibrated with buffer A. The column was washed with 10 CV of 
buffer B containing 1 M NaCl, 10 CV of buffer A and 10 CV of buffer A containing 10 
mM imidazole. The protein was eluted with 10 CV of buffer A containing 200 mM 
imidazole, subsequently diluted with 10 CV of buffer B containing 50 mM NaCl and 
further purified by cation exchange chromatography using a MonoS column (GE 
Healthcare). The column was equilibrated with buffer B and the complex was eluted 
with a linear gradient of 10 CVs from 0 mM to 1 M NaCl in buffer B. Subsequently, the 
sample was applied to a Superose 6 size exclusion column (GE Healthcare) 
equilibrated with buffer C. The protein was concentrated to approximately5 mg/ml, flash 
frozen in small aliquots in liquid N2 and stored at -80°C. 
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Med7N/31 (Sc) 
The cleared lysate from 2 liters of culture was loaded onto a 3 ml Ni-NTA column (Qiagen) 
equilibrated with buffer A. The column was washed with 20 CV of buffer A containing 20 
mM imidazole. The complex was eluted with buffer A containing 200 mM imidazole. 
followed by overnight cleavage with thrombin. The proteins were further purified by 
anion exchange chromatography using a MonoQ 10/100 column (GE Healthcare). The 
column was equilibrated with buffer B and the complex was eluted with a linear 
gradient of 20 CVs from 100 mM to 1 M NaCl in buffer B. After concentration, the 
sample was applied to a HiLoad Superdex-200 size exclusion column (GE Healthcare) 
equilibrated with buffer C. 
 
TFIIB (Sc) 
The cleared lysate from one liter of culture was incubated in batch (20 min / 4°C).with 2 
ml Ni-NTA material (Qiagen) equilibrated with buffer A containing 5 mM imidazole, 
0.2% Tween and protease inhibitor cocktail. After transferring the material to a gravity 
flow column, it was washed with 10 CV buffer A containing 10 mM imidazole. The 
protein was eluted with 3 CV of buffer A containing 200 mM imidazole. The sample was 
diluted with buffer B to a final conductivity of 50 mSi/cm and further purified by cation 
exchange chromatography using a MonoS 10/100 GL column (GE Healthcare). The 
column was equilibrated with buffer C and the complex was eluted with a linear 
gradient of 15 CVs from 100 mM to 1 M NaCl in buffer C. Subsequently, the sample 
was applied to a Superdex 75 10/300 GL size exclusion column (GE Healthcare) 
equilibrated with buffer D. 
 
Gal4-VP16 
The cleared lysate from three liters of culture was loaded twice onto a 2 ml Ni-NTA 
column (Qiagen) equilibrated with buffer A. The column was washed with 10 CV of 
buffer A, 10 CV of buffer B and 5 CV of buffer B containing 20 mM imidazole. The 
protein was eluted with 10 CV of buffer B containing 200 mM imidazole and further 
purified by anion exchange chromatography using a HiTrap Q HP column (GE 
Healthcare). The column was equilibrated with buffer C and the complex was eluted 
with a linear gradient of 10 CVs from 0 mM to 700 mM NaCl in buffer C. Subsequently, 
the sample was applied to a Superose 12 size exclusion column (GE Healthcare) 
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equilibrated with buffer D. The sample was concentrated to approximately0.5 mg/ml, 
flash frozen in small aliquots in liquid N2 and stored at -80°C. 
 
Gal4-AH 
The cleared lysate from three liters of culture was loaded twice onto a 2 ml Ni-NTA 
column (Qiagen) equilibrated with buffer A. The column was washed with 10 CV of 
buffer A, 10 CV of buffer B and 5 CV of buffer B containing 20 mM imidazole. The 
protein was eluted with 10 CV of buffer B containing 200 mM imidazole and further 
purified by anion exchange chromatography using a HiTrap SP column (GE 
Healthcare). The column was equilibrated with buffer C and the complex was eluted 
with a linear gradient of 10 CVs from 0 mM to 700 mM NaCl in buffer C. Subsequently, 
the sample was applied to a Superose 12 size exclusion column (GE Healthcare) 
equilibrated with buffer D. The sample was concentrated to approximately0.5 mg/ml, 
flash frozen in small aliquots in liquid N2 and stored at -80°C. 
 
Gcn4 
The cleared lysate from two liters of culture was loaded twice onto a 2 ml Ni-NTA 
column (Qiagen) equilibrated with buffer A. The column was washed three times with 
10 CV of buffer A containing 20 mM imidazole. The protein was eluted with 10 CV of 
buffer A containing 500 mM imidazole, subsequently diluted 1:5 with buffer B and 
further purified by cation exchange chromatography using a HiTrap SP column (GE 
Healthcare). The column was equilibrated with buffer B and the complex was eluted 
with a linear gradient of 10 CVs from 0 mM to 1 M NaCl in buffer B. Subsequently, the 
sample was applied to a Superdex 200 size exclusion column (GE Healthcare) 
equilibrated with buffer C. The sample was concentrated to approximately0.5 mg/ml, 
flash frozen in small aliquots in liquid N2 and stored at -80°C. 
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2.2.4 In vitro biochemical assays 
Yeast nuclear extract preparation, in vitro transcription and immobilized template assay 
were done as described (Ranish & Hahn, 1991; Ranish et al, 1999) with some 
changes.  
 
Yeast nuclear extract preparation 
For yeast nuclear extract preparation three liters of Sc were grown to 5x107 cells/ml in 
YPD containing 50 µg/ml ampicillin. Cells were harvested by centrifugation and the 
pellet was resuspended in 30 ml buffer A and incubated at 30°C for 15 min. Afterwards, 
cells were centrifuged and resuspended in 20 ml YPD/S, 3 ml 2 M sorbitol, 3 ml buffer 
A containing 18 mg zymolyase (Seikagaku) and protease inhibitor cocktail. Cells were 
incubated at 30°C for 15 – 60 min until at least 85% of cells were spheroblasted, then 
100 ml of YPD/S was added and cells were centrifuged. Pellet was resuspended in 250 
ml YPD/S and incubated at 30°C for 30 min. Afterwards cells were washed twice with 
200 ml ice-cold YPD/S and once with 200 ml 1 M ice-cold sorbitol. Cells were 
resuspended in 100 ml ice-cold buffer B and lysed on ice in a Dounce glass 
homogenizer (Kontes) with a small pestle. Crude nuclei were isolated by centrifuging 
(5000 rpm / 4°C / SLA-1500 rotor) two times for 8 min and two times for 5 min, 
transferring the supernatant each time to a new bottle. Afterwards nuclei were pelleted 
by centrifugation (13000 rpm / 30 min / 4°C / SS34 rotor), washed once with 15 ml 
buffer C, resuspended in 15 ml buffer C, flash frozen in liquid N2 and stored at -80°C. 
Nuclei were lysed by adding 3 M (NH4)2SO4 (pH 7.5 at 20°C) to a final concentration of 
0.5 M and incubation (30 min / 4°C / turning wheel). Afterwards nuclear lysate was 
ultracentrifuged (28000 rpm / 90 min / 4°C). Nuclear proteins in the supernatant were 
precipitated by addition of 0.35 g solid (NH4)2SO4 per ml and incubation (30 min / 4°C /  
turning wheel).  After centrifugation the nuclear proteins were resuspended in 250-1000 
µl of buffer D and dialysed for 4.5 h against buffer D containing 75 mM (NH4)2SO4.  
Nuclear extracts were flash frozen in liquid nitrogen and stored at -80°C. Concentration 
of nuclear extracts was determined by Bradford assay diluting the sample appropriately 
with 0.1% (w/v) SDS.  
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Pol II in vitro transcription with nuclear extracts 
Pol II in vitro transcription was done on various yeast promoter DNA templates inserted 
into pBluescript II KS+ plasmid (Table 9). The 25 µl transcription reaction mixture 
contained 1x transcription buffer, 200 µg yeast nuclear extract, 200 ng of template 
plasmid, 192 µg of phosphocreatine, 0.2 µg of creatine phosphokinase, 10 U of 
RiboLock RNase inhibitor (Fermentas) and 100 µM nucleoside triphosphates (NTPs). 
For activated transcription, 150 ng of recombinant Gal4-VP16, 200 ng of Gal4-AH or 
200 ng of recombinant Gcn4 was added. The reaction was incubated for 60 min at 
18°C. For temperature-sensitive yeast nuclear extracts the reactions were incubated 
for 45 min at 30°C. RNA was isolated using the RNeasy MinElute kit (Qiagen) 
according to the manufacturer’s manual. RNA was eluted from the column with 14 µl 
RNase-free H2O and in vitro transcripts were subsequently analyzed by primer 
extension. The 20 µl primer annealing reaction contained 1x annealing buffer, 12 µl 
eluate from RNeasy MinElute column and 0.125 pmol fluorescently labeled oligo (Table 
11). After boiling the samples 3 min at 95°C, the primer was annealed for 45 min at 
48°C. Afterwards, 40 µl synthesis mix containing 1x synthesis buffer, 0.15 mM dNTPs, 
12.5 u MuLV reverse transcriptase (Roche) and 1 µg actinomycin D, was added. The 
reverse transcription reaction was incubated for 30 min at 37°C. The resulting cDNA 
was EtOH precipitated and resuspended in 4 µl RNAse A (40 µg/ml). After incubating 3 
min at 18°C, 4 µl formamide sample buffer were added and the samples were boiled 
for 1 min. Transcripts were separated on a mini sequencing gel in 1x TBE buffer, 
scanned with a Typhoon 9400 and quantified with the ImageQuant software 
(GE Healthcare). 
 
Pol II immobilized template assay with nuclear extracts 
Pol II immobilized template assays were done on various linear yeast promoter 
templates. Templates were amplified by PCR from the in vitro transcription template 
plasmids (Table 9) using a biotin labeled forward primer and a regular reverse primer 
(Table 11). Afterwards, the PCR products were purified with the QIAquick PCR 
purification kit (Qiagen) followed by phenol chloroform extraction. For each reaction 
approximately 4.5 pmol of biotin labeled template were coupled to 200 µg of magnetic 
streptavidin beads (Dynabeads M-280, Invitrogen). Coupled beads were blocked for 15 
min at 20°C with bead blocking buffer and subsequently for 15 min at 20°C with 1x 
transcription buffer containing 0.5 mM biotin. After washing with 1x transcription buffer, 
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beads were resuspended in 20 µl 1x transcription buffer and 5 pmol recombinant Gcn4 
were added. After incubating for 10 min at 20°C while shaking, the beads were washed 
twice with 1x transcription buffer and resuspended in 20 µl 1x transcription buffer. A 
100 µl immobilized template reaction contained 20 µl of prepared beads, 1 mg yeast 
nuclear extract, 5 µg competitor DNA (HaeIII digested genomic E. coli DNA), 1x 
transcription buffer, 768 µg of phosphocreatine, 0.8 µg of creatine phosphokinase, 
0.05% NP-40 and 2.5 mM DTT. Assembly was done for 1 h at 4°C while shaking. 
Templates were washed twice with 1x transcription buffer containing 2 µg/ml 
competitor DNA, twice with 1x transcription buffer containing 500 mM K acetate and 
twice with 1x transcription buffer. Proteins were eluted by boiling beads in SDS-loading 
dye and subsequently analyzed by SDS-PAGE and Western blotting.  
 
Analysis of immobilized template assays by tandem mass spectrometry 
For tandem mass spectrometry analysis, 5 identical immobilized template reactions 
were prepared as described above and pooled after the last washing step. Proteins 
were eluted by boiling beads in SDS-loading dye and subsequently loaded on a 15% 
SDS-polyacrylamide gel. The proteins were run approximately 1 cm into the resolving 
gel. Then the gel was stained with Coomassie and destained as described above. 
Each lane was cut horizontally in eight equally sized gel slices. Afterwards, proteins 
were reduced, alkylated and digested with trypsin. Peptides were analyzed by tandem 
mass spectrometry using a LTQ Orbitrap (Thermo) in collaboration with the Prof. Axel 
Imhof laboratory (LMU, Munich). Proteins were identified using MASCOT 
(www.matrixscience.com) and quantified label-free using spectral count analysis (Zhu 
et al, 2010). 
 
Electrophoretic mobility shift assays  
Binding reactions (20 µl) contained 5 pmol Gal4-VP16 and 5, 50 or 150 pmol ACID 
variants. We used 1 pmol of a DNA duplex containing a single Gal4-binding site (Table 
11). After incubation for 20 min at room temperature, ACID variants were added 
accordingly, and the mixture was incubated for 10 min. Formed complexes were 
separated on 5% acrylamide gels in TGOE buffer (0.25 M Tris, pH 8.3, 1.9 M glycine). 
Bands were quantified with a Typhoon 9400 scanner and the ImageQuant Software 
(Amersham Biosciences). 
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2.2.5 Yeast methods 
Cryo-stocks of yeast strains 
A single colony was restreaked on a YPD plate and incubated for 2 days at 30°C. All 
cells from the plate were transferred to 1 ml sterile 40 % v/v glycerol, vortexed and 
flash-frozen in liquid nitrogen. Cryo-stocks were stored at -80°C. 
 
Yeast transformation 
50 ml of YPD medium were inoculated with a pre-culture grown over night to a starting 
OD600 of 0.1 and grown to a final OD600 of 0.8 (30°C / 160 rpm). Cells were harvested 
by centrifugation (2500 rpm / 5 min / 4°C) and washed with 25 ml ddH2O. Afterwards, 
the cells were washed with 1 ml 100 mM lithium acetate, then resuspended in 400 µl 
100 mM lithium acetate and divided into 100 µl aliquots. After centrifugation (max. 
speed / 15 sec) the supernatant was discarded and 240 µl 50% (w/v) PEG 3350, 36 µl 
1 M lithium acetate, 50 µl boiled salmon sperm DNA (2 mg/ml) and 34 µl DNA (1-5 µg 
linear DNA or 200 ng plasmid DNA) were added. The cells were vortexed vigorously for 
1 min, incubated for 30 min at 30°C and then heat-shocked for 15 min at 42°C. 
Afterwards, cells were centrifuged (max. speed / 15 sec), the supernatant discarded 
and the pellet resuspended in 200 µl YPD medium. After recovery (30°C / 1 h / 
shaking), cells were centrifuged again and the pellet resuspended in 200 µl ddH2O. 50 
µl of the suspension was plated on the respective drop-out plates and incubated for 2-3 
days at 30°C.  
 
Sporulation and tetrad dissection 
Freshly grown diploid cells were restreaked on sporulation plates and incubated for 
several days at 30°C. Sporulation was monitored under the light microscope. When at 
least 5% of the cells had sporulated, a loop full of cells was washed twice with 500 µl 
ddH2O and resuspended in 100 µl ddH2O. The outer cell wall of the tetrads was 
destroyed by adding 10 µl Glusulase (Perkin-Elmer). After 5 min incubation at room 
temperature, suspension was put on ice and 400 µl of ddH2O were added. Fraction of 
cell suspension was streaked out on a YPD plate and spores were dissected using a 
tetrad microscope. Tetrads with four growing spores were restreaked on YPD plates 
and corresponding drop out plates to check for marker segregation.  
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Complementation assays 
To assess the phenotype of mutants, yeast complementation assays were performed. 
The respective shuffle strain, carrying a genomic knockout of the gene of interest and 
wild-type copy of the gene including promoter and terminator on plasmid pRS316, was 
used. Various constructs including the promoter and terminator region on plasmid 
pRS315, typically empty plasmid, wild-type gene and mutated gene, were transformed 
into the respective shuffle strain. After selection on drop-out plates, equal amounts of 
freshly grown yeast cells in SDC (-Ura/-Leu) were resuspended in water and and ten-
fold dilutions were spotted on 5-FOA and SDC (-Ura/-Leu) plates. Viable mutant strains 
were streaked twice on 5-FOA plates and then on SDC (-Leu). Equal amounts of 
freshly grown yeast cells in SDC (-Leu) were resuspended in water, ten-fold dilutions 
were spotted on YPD plates and plates were subsequently incubated at 30°C and 37°C 
to assess fitness and temperature sensitivity. 
 
Growth curves 
Growth curves were recorded by inoculating 50 ml YPD medium with a pre-culture 
grown over night to a starting OD600 of 0.1. The culture was grown at 30°C / 160 rpm 
for at least 10 h. Growth was monitored by measuring the OD600 of the culture every 
hour.  
 
Tandem affinity purification 
Tandem affinity purification (TAP) from 3 l of yeast culture (5x107 cells/ml) was 
essentially done as described (Puig et al, 2001).  
 
Denaturing protein extraction 
Denaturing protein extraction from yeast cells was carried out essentially as described 
(Knop et al, 1996). A 5 ml yeast culture was grown in YPD overnight (30°C / 160 rpm). 
5 OD600 of cells were washed with 1 ml ddH2O and subsequently resuspended in 500 
µl ddH2O. After addition of 150 µl 1.85 M NaOH containing 7.5% (v/v) β-
mercaptoethanol, the suspension was incubated for 20 min on ice. Proteins were 
precipitated by adding 150 µl of 55% trichloroacetic acid and incubation for another 20 
min on ice. After centrifugation (max. speed / 20 min / 4°C / table top centrifuge), the 
supernatant was removed and 1 ml of acetone added. After centrifugation (max. speed 
/ 10 min / 4°C / table top centrifuge) the pellet was air-dried. 100 µl of 2x SDS sample 
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buffer and 20 µl of 1 M Tris base were added. Samples were boiled for 2 min at 95°C 
before loading on a SDS-PAGE. 
 
Immunoprecipitation from whole cell extracts 
A 50 ml yeast culture was grown in YPD (30°C / 160 rpm) to an OD600 of approximately 
5. Cells corresponding to 160 OD600 were harvested by centrifugation, washed once 
with 25 ml ddH2O and resuspended in 1 ml TAP lysis buffer containing protease 
inhibitor cocktail and 0.5 mM DTT. Cell suspension was transferred to a 2 ml tube and 
1 ml of 0.5 mm Zirconia beads (Roth) were added. Cells were lysed in in a mixer mill 
(Retsch) for 30 min at 4°C. Lysate was transferred to a new tube and centrifuged (max. 
speed / 30 min / 4°C). 100 µl of the cleared lysate were set aside as input control. To 
the remaining sample the detergent Igepal CA-630 (Sigma) was added to a final 
concentration of 0.05%. 20 µl of IgG-coupled magnetic beads (Invitrogen) were 
washed twice twice with TAP lysis buffer containing 0.05% Igepal CA-630. Washed 
beads were added to the lysate and incubated on a turning wheel for 45 min at 4°C. 
Magnetic beads were subsequently washed 5 times with 1 ml TAP lysis buffer 
containing 0.05% Igepal CA-630, protease inhibitor cocktail and 0.5 mM DTT. After 
removing the last wash, 30 µl of 2x SDS sample buffer were added to the beads and 
samples were boiled for 2 min at 95°C.  
 
Chromatin immunoprecipitation 
All chromatin immunoprecipitation experiments were performed in biological duplicates 
in YPD as previously described in detail (Aparicio et al, 2005; Mayer et al, 2010). Since 
the Med11/22 mutant strains displayed severe growth defects and larger cell sizes 
compared to wild-type, cells were counted instead of measuring optical density. To 
minimize the risk of acquiring a rescue mutation and ensure biological significance of 
our observations, the used biological duplicates were already separated before 
shuffling out the respective rescue plasmid and several rounds of selection. Phenotype 
and growth was monitored closely at each step. Overnight cultures were diluted in 
fresh medium to 1x106 cells/ml (40 ml cultures, 160 rpm shaking incubator, 30°C) and 
grown to mid-log phase (1x107 cells/ml) before formaldeyde crosslinking. Input and 
immunoprecipitated samples were assayed by quantitative real-time PCR to assess 
occupancy of proteins at three different promoters. Primer pairs directed against the 
promoter of the highly transcribed ILV5 gene, the housekeeping gene ADH1, the 
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glucose-repressed GAL1 gene as well as against a heterochromatic control region of 
chromosome V were designed (Table 12) and the corresponding PCR efficiencies 
determined. All primer pairs used in this study had PCR efficiencies in the range of 
95-­‐100%. 25 µl PCR reactions contained 1 µl DNA template, 2 µl of 10 µM primer pairs 
and 12.5 µl iTaq SYBR Green Supermix (Bio-­‐Rad). Quantitative PCR was performed 
on a CFX96 Real-­‐Time System (Bio-­‐Rad) using a 3 min denaturing step at 95°C, 
followed by 49 cycles of 30 s at 95°C, 30 s at 61°C and 15 s at 72°C. Threshold cycle 
(Ct) values were determined using the Ct determination mode “Regression” of Bio-­‐Rad 
CFX Manager software package (Version 1.1). Fold enrichment over heterochromatic 
control region was determined and calculated as described (Aparicio et al, 2005).  
 
2.2.6 Gene-expression profiling 
Experimental setup for „Structure-system correlation defines the gene regulatory 
Mediator submodule Med8C/18/20“ (see Chapter 3.1) 
Gene expression profiling was done in collaboration with the laboratory of Prof. F. 
Holstege (University Medical Center Utrecht). All strains except med8C∆ are as 
described (van de Peppel et al, 2005). med8C∆ is isogenic to S288c. Truncation was 
made by using the ADH1 terminator from pFA6a-13myc-kanMX6 (Longtine et al, 
1998). All experiments were performed in SC medium with 2% glucose. For microarray 
analysis, two independent colonies were inoculated and overnight cultures were diluted 
in fresh medium to an OD600 of 0.15 (60 ml cultures, 250 rpm shaking incubator 30°C). 
Cells were harvested by centrifugation (4000 rpm, 3 min) at an OD600 of 0.6, and pellets 
were frozen in liquid nitrogen. The RNA reference was obtained as described (van de 
Peppel et al, 2003). Total RNA was prepared by hot phenol extraction. Additionally, 
RNA was treated with DNase (Qiagen) and cleaned up using the RNAeasy kit 
(Qiagen). The mRNA was amplified by in vitro transcription using T7 RNA polymerase 
on 1 µg of total RNA. During in vitro transcription, 5-(3-aminoallyl)-UTP (Ambion) was 
incorporated into the single-stranded cRNA. Cy3 or Cy5 fluorophores (Amersham) 
were coupled to 3 µg of cRNA. Before hybridization, free dyes were removed using 
RNAClean (Agencourt), and the efficiency of cDNA synthesis and dye incorporation 
was measured using a spectrophotometer (SpectraMax190, Molecular Devices). C6-
amino-linked oligonucleotides (70 nucleotides in length), the Yeast Genome 
ArrayReady (Operon) were purchased from Qiagen and were printed on Codelink 
slides following manufacturers instructions (GE Healthcare) with a MicroGrid II 
MATERIALS AND METHODS 
47 
 
(Apogent Discoveries) using 48-quill pins (Microspot2500; Apogent Discoveries). Each 
gene is represented twice and the arrays additionally contained 2838 control features 
for external control normalization and QC (van de Peppel et al, 2003). From each 
sample, 2 µg cRNA (with a specific activity of 2–6% dye-labeled nucleosides) was 
hybridized, together with 2 µg cRNA from the reference, for 16–20 h at 42 °C (Agilent 
microarray hybridisation chamber). After scanning (G2565AA Agilent scanner, 100% 
laser power, 30% photomultiplier tube), raw data was extracted with Imagene 7.5 
(Biodiscovery). After image quantification and local background subtraction, all 
negative values were replaced with the standard deviation of the local background. 
Print-tip with a span of 0.4 was applied to normalize genes (Yang et al, 2002). After 
averaging of duplicate spots for each gene on the array, data were visualized and 
clustered with GeneSpring 7.2 (SiliconGenetics). For each mutant individually, the 
replicate profiles were compared to the replicate wt profiles through the common 
reference with ANOVA (R/MAANOVA version 0.98-7 http://cran.r-
project.org/src/contrib/Descriptions/ maanova.html). In a fixed effect analysis, sample, 
array, spot, and dye effects were modeled. P-values were determined by a permutation 
F2 test in which residuals were shuffled 5000 times, Benjamini-Hochberg multiple-
testing correction was applied. Genes with p < 0.05 and an average fold change over 
the four measurements of at least 1.7 were considered significant. Pearson’s 
correlation was calculated in Microsoft Excel. For each pair of deletion strains the 
respective lists of significantly changed genes were merged and the respective 
correlation coefficient (R-value) was calculated. 
Overrepresented biological processes for genes with significant expression changes 
were determined using GO Slim Mapper (http://db.yeastgenome.org/cgi-
bin/GO/goSlimMapper.pl) based on the GO database (Ashburner et al, 2000). GO Slim 
Mapper distributes genes to 32 different biological processes according to their GO 
annotation. Additionally it provides the corresponding genomic background level for 
each process. All genes categorized with the GO term “Biological process” or “not 
mapped” were listed together as “not annotated”. 
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Experimental setup for „Mediator head subcomplex Med11/22 contains a 
common helix bundle building block with a specific function in transcription 
initiation complex stabilization“ (see Chapter 3.2) 
Gene expression profiling was done in the laboratory of Prof. P. Cramer. All 
experiments were performed in YPD medium with 2% glucose. For microarray 
analysis, at least two independent colonies were used for inoculation and overnight 
cultures were diluted in fresh medium to 1x106 cells/ml (25 ml cultures, 160 rpm 
shaking incubator, 30°C). Cells were harvested in early log-phase (1x107 cells/ml) by 
centrifugation. Total RNA was prepared after cell lysis using a mixer mill (Retsch) and 
subsequent purification using the RNAeasy kit (Qiagen). The total RNA preparation 
was treated on-column with DNase (Qiagen). All following steps were conducted 
according to the Affymetrix GeneChip Expression Analysis Technical Manual (P/N 
702232 Rev. 2). Briefly, one-cycle cDNA synthesis was performed with 1 µg of total 
RNA. In vitro transcription labeling was carried out for 16 h. The fragmented samples 
were hybridized for 16 h on Yeast Genome 2.0 expression arrays (Affymetrix), washed 
and stained using a Fluidics 450 station, and scanned on an Affymetrix GeneArray 
scanner 3000 7G. Data analysis was performed using R/Bioconductor (Gentleman et 
al, 2004). S. pombe probes were filtered out prior to normalization with the GCRMA 
algorithm (Wu et al, 2004). Linear model fitting and multiple testing correction using an 
empirical Bayes approach was performed using the LIMMA package (Smyth, 2004). 
Differentially expressed genes were defined as having an adjusted p-value smaller 
than 0.05 and an estimated fold change of at least 2.0 (calculated as the fold change of 
the average expression in the replicate measurements). Hierarchical clustering was 
calculated using TIGR MeV application (Saeed et al, 2003). Microarray data were 
submitted to the ArrayExpress database (http://www.ebi.ac.uk/microarray). Pearson’s 
correlation coefficients were calculated as described above. Overrepresented biological 
processes for genes with significant expression changes were determined using GO 
Term Finder tool (http://go.princeton.edu/cgi-bin/GOTermFinder) based on the GO 
database (Ashburner et al, 2000). 
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3 Results and Discussion 
3.1 Structure-system correlation defines the gene regulatory 
Mediator submodule Med8C/18/20 
3.1.1 Med8C/18/20 is a subcomplex of the Mediator head 
Previous results had revealed that Sc Med8 contains an essential N-terminal domain 
(Med8N, residues 1–137), followed by a nonessential linker (residues 138–189) and a 
C-terminal region that includes a α-helix (Med8C, residues 190–223) (Larivière et al, 
2006). Med8C had been proposed to tether the Med18/20 heterodimer to the essential 
part of the Mediator head (Figure 4A).  
 
 
 
Figure 4: Med8C/18/20 is a subcomplex of Mediator head.  
(A) Overview of the Mediator architecture with the four modules head, middle, tail, and kinase. The head 
module is separated in the core head, constituted of Med6, Med8N, Med11, Med17, Med22, and the 
nonessential subcomplex of Med8C, Med18, and Med20 (in orange, blue, and magenta, respectively).  
(B) Deletion of Med8C in vivo leads to loss of Med18/20 after Mediator purification. N-terminally TAP-
tagged Med17 was purified from wild-type yeast or from cells expressing Med8CΔ. The EGTA eluate after 
purification was separated using 4%–12% discontinuous SDS-PAGE and was analyzed by mass 
spectrometry after Coomassie staining. The copurifying proteins were identified by mass spectrometry. 
Arrows mark Med8, Med8CΔ, Med18, and Med20. An asterisk indicates TAP-tagged Med17. 
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To test this, we asked whether Med8C tethers the Med18/20 heterodimer to Mediator 
in vivo. We isolated Mediator by tandem affinity purification (TAP) from yeast strains 
expressing a TAP-tagged head subunit, Med17, and identified the copurifying Mediator 
subunits by mass spectrometry (Figure 4B). The same purification from a strain 
expressing a truncated version of Med8 that lacked Med8C (med8CΔ) resulted in a 
very similar pattern of protein bands, except that Med18 and Med20 were missing 
(Figure 4B). Therefore, retention of Med18 and Med20 in the Mediator complex 
requires Med8C. The truncated Med8 variant was, however, present in the preparation, 
showing that Med8C is not required to retain Med8 in the Mediator. These data are 
consistent with interaction data derived by coexpression and two-hybrid analysis 
(Guglielmi et al, 2004; Takagi et al, 2006) and suggest that the head contains two 
structural subcomplexes, the core head, consisting of all essential head subunits or 
subunit domains (Med6, Med8N, Med11, Med17, and Med22) and the nonessential 
Med8C/18/20 subcomplex (Figure 4A). 
 
Table 19: Data collection and refinement statistics for the Sp Med8C/18 structure 
a The numbers in parenthesis correspond to the highest resolution shell  
b 5% of the data were excluded from the refinement for free R-factor calculation 
                                                                RESULTS AND DISCUSSION 
51 
 
3.1.2 Conserved Med8C/18/20-core head interface 
Because of the low sequence homologies between Mediator subunits from different 
species, the architecture of the Sc head could be a species-specific feature. To inves- 
tigate this, we solved the crystal structure of the Med8C/18 complex from 
Schizosaccharomyces pombe (Sp). We coexpressed Sp Med18 with a hexahistidine-
tagged Sp Med8C fragment corresponding to the Sc Med8C fragment used previously 
(Larivière et al, 2006) from a bicistronic vector in E. coli. The Sp Med8C fragment was 
sufficient for interaction with Sp Med18. The resulting stoichiometric Med8C/18 
complex was crystallized and the structure solved (Table 19). Sp Med18 adopts a fold 
similar to its Sc ortholog (Figure 5A) with a root mean square deviation of 1.7 Å over 
173 Cα! atoms.  
 
 
Figure 5: Structural conservation of the Med8C/18 interaction 
(A) Superimposition of Cα traces of Med8C/18 from Sp (in cyan and red; this study) and from Sc (in blue 
and orange; (Larivière et al, 2006)). Med20 is shown in magenta. (B) Interaction of Sp Med8C with  
Sp Med18. The Med8C helix is shown in red sticks, with conserved or invariant residues in contact with 
Med18 labeled in red. Med18 is shown as a white surface, with conserved or invariant residues in contact 
with Med8C labeled in black. Residues that are invariant and conserved between Sc and Sp are in green 
and yellow, respectively.  
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Sp Med8C forms a α-helix, followed by a glycine-containing turn, and binds Sp Med18 
across its central β-barrel as observed for its Sc counterpart (Figure 5A). Key contact 
residues in the Med8C–Med18 interface are conserved between Sc and Sp (Figure 
5B). Given the large phylogenetic distance between these two fungi, the Med8C/18 
interface is apparently also conserved in Mediator complexes of higher eukaryotes. 
Indeed, modeling of the human Med8C–Med18 interface showed that key contacts are 
conserved. Thus, the structural tethering of the Med18/20 heterodimer to the core head 
module through Med8C is conserved among eukaryotes. 
 
3.1.3 Med8C/18/20 is required for activated transcription in vitro 
To investigate whether the structural subcomplex Med8C/18/20 is also a functional 
subcomplex of Mediator, we conducted in vitro transcription assays. We prepared 
nuclear extracts from yeast strains carrying a deletion of the gene for Med18 (med18Δ) 
or lacking the part of the Med8 gene coding for Med8C (med8CΔ).  
 
 
Figure 6: Med8C/18/20 is required for activated transcription in vitro.  
Med8C/18/20 is required for activated transcription in vitro. Assays were performed with med18Δ or 
med8CΔ nuclear extracts (lane 1), or extract to which 0.5 pmol TAP-purified Mediator was added, 
providing a positive control (lane 2), or extracts to which recombinant Med8C/18/20 (10x and 100x molar 
excess in lanes 3 and 4, respectively) or recombinant Med18/20 (10x and 100x molar excess in  
lanes 5 and 6, respectively) were added. 
 
 
Consistent with previous data (Ranish et al, 1999; Thompson et al, 1993), a med18Δ 
nuclear extract did not support activated transcription (Figure 6, lane 1), apparently as 
a result of Mediator lacking Med18 and Med20 in this mutant. The transcription defect 
could indeed be rescued by addition of recombinant Med18/20 (Figure 6, lanes 5 and 
6). This is consistent with the model that Med8C, which is present in the extract, tethers 
Med18/20 to the Mediator. Recombinant Med8C/18/20 subcomplex was far less 
efficient in rescue (Figure 6, lanes 3 and 4), likely because endogenous Med8C fails to 
replace recombinant Med8C for tethering Med18/20. Consistently, a nuclear extract 
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from the med8CΔ strain was inactive (Figure 6, lane 1), apparently as a result of 
Mediator lacking Med18 and Med20. Even a large excess of Med18/20 could not 
rescue the defect (Figure 6, lanes 5 and 6), but recombinant Med8C/18/20 could 
partially restore transcription (Figure 6, lanes 5 and 6). Thus, Med8C is essential for 
activated transcription in this assay. Since providing Med8C in trans can partially 
rescue the defect, Med8C apparently also interacts non-covalently with the core head, 
consistent with a reported two-hybrid interaction between Med8C and Med17 
(Guglielmi et al, 2004). These functional data are consistent with the two-subcomplex 
architecture of the head (Figure 4A), and highlight the critical functional role of Med8C 
in tethering the two subcomplexes together. 
 
3.1.4 Med8C/18/20 is a functional submodule in vivo 
To test whether the ‘two-subcomplex architecture’ of the Mediator head underlies 
Mediator function in vivo, and to determine whether the only role of Med8C is to tether 
Med18/20, we carried out comparative gene expression profiling with different yeast 
deletion strains. If the only role of Med8C is tethering of Med18/20 to Mediator, then the 
changes in gene expression observed in a Med8C deletion should be essentially the 
same as for deletion of either Med18 or Med20. We first used three strains of the same 
genetic background but specifically lacking one component of the Med8C/18/20 
subcomplex. The expression profiles for these med8CΔ, med18Δ, and med20Δ 
deletion strains showed virtually the same pattern of changes in mRNA levels (Figure 
7A). This is reflected in very high pairwise overall correlations (Figure 7B). For 
comparison, we repeated the analysis with two deletion strains that lacked genes for 
nonessential subunits Med2 or Med3 that reside in the tail module and also play a 
positive role in transcription (van de Peppel et al, 2005). Expression changes induced 
by Med2 or Med3 deletion correlate weakly with those induced by deletion of 
Med8C/18/20 components, although there is some overlap (Figure 7A and B). 
Therefore, the Med8C/18/20 subcomplex regulates transcription of a specific subset of 
genes and forms a functional submodule in vivo. The similarity in expression profiles is 
in agreement with the idea that the only role of Med8C is to tether Med18/20 to the 
core head. These results highlight the possibility to correlate structural data with 
transcriptome profiles, thereby identifying proteins and protein domains that reside in 
the same functional module. 
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Figure 7: Comparative gene expression profiling 
(A) Diagram of genes exhibiting significantly altered mRNA levels (vertical axis) for different Mediator 
deletion strains (horizontal axis), clustered alongside the med18Δ, med20Δ, and med8CΔ expression 
profiles (indicated by black bar). Changes in mRNA levels compared with the wild-type strain are depicted 
in red (up), green (down), or black (no change). (B) Pearson’s correlation matrix for expression profiles of 
strains med8CΔ, med18Δ, and med20Δ, and tail subunits deletion strains med2Δ and med3Δ. (C) Number 
of significantly altered genes in all three deletion strains of the Med8C/18/20 submodule. Genes not 
annotated in the GO database are depicted in gray, up-regulated genes are indicated in red, and down-
regulated genes are shown in green. (D) Percentage of genes for which expression was significantly 
changed in all deletion mutants of the Med8C/18/20 (blue) submodule or Med2 and Med3 (yellow) 
compared with the percentage of the genome (black). All 32 biological processes from GO Slim Mapper 
are shown as follows: amino acid derivative metabolic process (1), anatomical structure morphogenesis 
(2), carbohydrate metabolic process (3), cell budding (4), cell cycle (5), cell wall organization and 
biogenesis (6), cellular homeostasis (7), cellular respiration (8), conjugation (9), cytokinesis (10), 
cytoskeleton organization and biogenesis (11), DNA metabolic process (12), electron transport (13), 
generation of precursor metabolites and energy (14), lipid metabolic process (15), meiosis (16), membrane 
organization and biogenesis (17), nuclear organization and biogenesis (18), organelle organization and 
biogenesis (19), protein catabolic process (20), protein modification process (21), pseudohyphal growth 
(22), response to stress (23), ribosome biogenesis and assembly (24), RNA metabolic process (25), signal 
transduction (26), sporulation (27), transcription (28), translation (29), transport (30), vesicle-mediated 
transport (31), and vitamin metabolic process (32). Overrepresented processes are marked with a circle. 
(E) Percentage of genes involved in conjugation, sporulation, and vitamin metabolic process for which 
expression was significantly changed in all deletion mutants of the Med8C/18/20 submodule or Med2 and 
Med3. Red and green histograms correspond to up- and down-regulated genes, respectively. The dotted 
line represents the percentage of the genome involved in the respective process. 
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3.1.5 Med8C/18/20 is required for transcription of specific genes 
Analysis of the expression profiles revealed that a total of 165 mRNA levels were 
significantly altered in all three deletion strains of the Med8C/18/20 submodule. Of 
those, 117 were down-regulated, and 48 were up-regulated, showing that the module 
predominantly acts as a positive factor in transcription, but can also act as a negative 
factor for certain genes. Of the down- and up-regulated genes, 44% and 37%, 
respectively, were not annotated in the gene ontology (GO) database (Figure 7C) 
(Ashburner et al, 2000). Since it was previously shown that Med8C/18/20 binds to the 
TATA box-binding protein (TBP) in vitro (Larivière et al, 2006), we were encouraged to 
unravel a molecular basis for Med8C/18/20 function by searching for reoccurring 
promoter elements or upstream motifs in the deregulated genes, and for common 
transcription factors known to regulate these genes. This search was, however, 
unsuccessful, suggesting a complex context-dependent mechanism of Med8C/18/20 
function. 
We next analyzed the cellular function of genes regulated by Med8C/18/20 and by 
Med2 or Med3 with the GO Slim Mapper tool. Many of the affected biological 
processes, including amino acid derivative metabolism, carbohydrate metabolic 
process, and vitamin metabolic process, were overrepresented in both the 
Med8C/18/20-regulated and Med2/3-regulated genes (Figure 7D), reflecting the partial 
overlap of the expression profiles (Figure 7A). However, some biological processes 
were overrepresented only among Med8C/18/20- or Med2/Med3-regulated genes. In 
particular, genes involved in conjugation were specifically Med8C/18/20-regulated, 
whereas genes involved in sporulation as well as cell wall organization and biogenesis 
were specifically Med2/Med3-regulated (Figure 7E). These findings are consistent with 
the previously reported involvement of Med18 in conjugation (Holstege et al, 1998) and 
with a large-scale functional genomics analysis of sporulation efficiency (Enyenihi & 
Saunders, 2003). 
 
3.1.6 Down-regulation of nonactivated genes and basal promoter activity 
Down-regulation of conjugation genes in med8CΔ, med18Δ, and med20Δ deletion 
strains was surprising, since their transcription was expected to be repressed under our 
experimental conditions. However, the same phenomenon was observed for other 
genes that should be repressed under optimal growth conditions. The GAL4 gene is 
further down-regulated in the med8CΔ, med18Δ, and med20Δ deletion strains, but not 
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in the control strains med2Δ or med3Δ. Genes involved in the catabolism of serine and 
glycine are further down-regulated in all deletion strains, including CHA1, GCV1, 
GCV2, and GCV3. CHA1 shows the most down-regulated transcript levels, although it 
is expected to be expressed only under nitrogen-limiting conditions. Thus, 
Med8C/18/20 is required for low levels of transcription of nonactivated genes. 
Taken together, many genes that are repressed under our growth conditions were 
apparently transcribed at a low level in a Med8C/18/20-dependent manner. The 
requirement of Med8C/18/20 for low-level transcription of nonactivated genes is 
consistent with the observation that even low levels of transcription require Mediator 
(Kornberg, 2005; Takagi et al, 2006). Although an indirect effect cannot be ruled out, 
our data suggest that Med8C/18/20 is important for basal promoter activity, and are 
consistent with a possible TBP interaction in vivo. A role of Mediator in basal 
transcription may be further investigated by similar analyses of other Mediator 
submodules and transcriptome profiling of several mutant yeast strains under various 
growth conditions. 
 
3.1.7 Discussion 
The Mediator head module is essential for cell viability, and a temperature-sensitive 
point mutation in the head leads to a global defect in transcription (Holstege et al, 
1998). Here, we show that the head module contains the distinct conserved 
Med8C/18/20 submodule that is not essential for viability and regulates only a subset of 
genes. Identification and characterization of the Med8C/18/20 submodule required a 
combination of structural biology, yeast genetics, biochemistry, and transcriptome 
analysis. Our results support the idea that the known Mediator modules head, middle, 
and tail contain distinct submodules with different functions that are involved in the 
regulation of different subsets of genes. 
More generally, we demonstrate how structural and functional information obtained on 
the molecular level in vitro can be correlated with changes on the systems level in vivo. 
In particular, the structure-guided design of mutant yeast strains enabled a precise 
disruption of molecular interactions and their functional analysis in vitro and in vivo. 
This approach is superior to the generally used gene deletion analysis, which does not 
take into account the consequences of such deletions for native protein complex 
structures. Most proteins reside in complexes (Gavin et al, 2006; Gavin et al, 2002; 
Krogan et al, 2006), and gene deletion will often result in complex disintegration and 
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malfunction, and thus in complicated changes of the transcriptome, which renders 
correlations between the molecular and the systems level difficult or impossible. In 
contrast, the structure-based systems perturbation analysis conducted here reduces 
the complexity of differential gene expression patterns, and facilitates the dissection of 
transcriptional coregulatory complexes into distinct functional submodules. In the 
future, this approach may be used for a reliable analysis of gene regulatory molecular 
networks. In particular, structure-based perturbation of cooperative molecular 
interactions could elucidate combinatorial and context-dependent gene regulatory 
mechanisms on the system level. 
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3.2 Mediator head subcomplex Med11/22 contains a common 
helix bundle building block with a specific function in 
transcription initiation complex stabilization 
3.2.1 Revised Med11 N-terminus 
Based on published interaction data (Esnault et al, 2008; Guglielmi et al, 2004; Takagi 
et al, 2006) we assumed that Sc Med11 and Med22 form a stable heterodimer. Indeed, 
the two subunits could be co-expressed in recombinant form (Larivière et al, 2006) in 
E. coli and subsequently co-purified. When we analyzed recombinant Med11/22 and 
endogenous purified Mediator by SDS-PAGE, we noticed a discrepancy in the 
electrophoretic mobility of Med11 (not shown). A comparison of the annotated Med11 
open reading frame (ORF) with experimentally determined transcription start sites 
(Miura et al, 2006) revealed that the start codon of Med11 was incorrectly assigned in 
the databases. The real initiator methionine corresponds to residue 17 of the original 
annotation. We corrected the amino acid numbering and used the new numbering 
throughout. 
 
3.2.2 Med11/22 structure solution 
We prepared the correct full-length recombinant Med11/22 heterodimer in pure 
recombinant form. In contrast to the initial preparation, this complex crystallized. The 
crystals could however not be refined, likely due to flexibility in the poorly conserved  
C-termini of both subunits. We therefore tested various truncated protein variants for 
their solubility and crystallization behavior, and found that a variant comprising the 
highly conserved core of Med11/22 (Med115-89/Med221-89, Figure 8A) resulted in 
crystals diffracting up to a resolution of 2.1 Å. The X-ray structure was solved by 
selenomethionine labeling and multi-wavelength anomalous diffraction, and was 
refined to a free R-factor of 20.8 % (Table 20). The crystals contained an unusual 
sphere-like arrangement of 12 heterodimers in the asymmetric unit (Figure 8B). 
Disordered in the crystals was only a non-conserved Med22 linker (residues 33-40) 
between helix α1 and the non-conserved helix α*. Deletion of this linker in yeast had no 
phenotype (Figure 9A). 
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Figure 8: Structure of Med11/22 Mediator subcomplex 
(A) Multiple sequence alignment of the conserved core of Med11 and Med22 from Saccharomyces 
cerevisiae (Sc), Schizosaccharomyces pombe (Sp), Caenorhabditis elegans (Ce), Drosophila 
melanogaster (Dm) and Homo sapiens (Hs). The corrected numbering of Sc Med11 is used. Invariant and 
conserved residues are highlighted in green and yellow, respectively. Additionally, residues that are 
invariant or conserved among the yeast family Saccharomycotinae (Sc, Candida glabrata, Candida 
albicans, Ashbya gossypii, Kluyveromyce lactis and Debaryomyces hansenii) are highlighted with green 
and yellow frames on the Sc sequence, respectively. Surface accessibility is indicated below the 
sequences (blue, high; cyan, intermediate; white, buried). Secondary structure elements of the conserved 
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structural core are shown above the sequences (spirals, α-helices; lines, ordered but without secondary 
structure; dashed lines, disordered in crystal construct). In addition schematic views of the full proteins are 
shown. Consensus secondary structure predictions (Cuff & Barton, 1999; Jones, 1999; Ouali & King, 
2000) for the C-termini of Sc Med11 and Med22 are indicated with dashed lines and grey filling. All 
truncations relevant for this study are indicated with arrows and the residue number. Previously reported 
as well as mutations generated in this study are marked with black triangles. Sequence alignments were 
done with MUSCLE (Edgar, 2004) and figures were prepared with ESPript (Gouet et al, 1999). (B) Ribbon-
model representation of the 12 heterodimers within the asymmetric unit. Med11 and Med22 are depicted in 
brown and cyan, respectively. (C) Ribbon-model representation of the Med11/22 crystal structure. 
Secondary structure elements are labeled according to (A). The linker between helices α1 and α* of 
Med22 (residues 33-40) was disordered. C-termini of Med11 and Med22 had to be removed from 
crystallization construct and are therefore lacking in the structure. (D) Dimer interface conservation. On the 
left, Med11 is shown in surface representation together with a ribbon model of Med22. The view is related 
to (C) by a 90° rotation around a vertical axis. On the right, Med22 is shown in surface representation 
together with a ribbon model of Med11. The two views are related by a 180° rotation around a vertical axis. 
(E) Superimposition of Cα traces of the four-helix bundle folds of Med11/22 (brown and cyan; this study) 
and Med7C/21 (orange and purple; (Baumli et al, 2005)). (F) Ribbon-model representation of the complete 
Med7C/21 structure (pdb accession code 1YKE). The reported flexible hinge region is indicated. 
 
 
Table 20: Data collection and refinement statistics for Med11/22 structure 
a The numbers in parenthesis correspond to the highest resolution shell 
b 5% of the data were set aside for free R-factor calculation 
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3.2.3 A helix bundle building block in Mediator 
Med11/22 forms an anti-parallel four-helix bundle (Figure 8C). This bundle fold is 
required in vivo since deletion of Med11 helix α1 (med1143-115) was lethal in yeast, and 
deletion of α1 and α* of Med22 (med2254-121) caused a growth defect (Figure 9B). 
 
 
 
 
 
 
 
 
Figure 9: In vivo phenotyping of Med11/22 
truncations 
Yeast complementation assays. Med11 and Med22 
constructs including 500 bp upstream of the start 
codon and 300 bp downstream of the stop codon 
were cloned into a pRS315 plasmid (LEU2) and 
transformed into the respective yeast shuffle strains. 
On 5FOA plates the URA3 shuffle plasmid encoding 
the respective full-length gene is shuffled out. Yeast 
cells lacking either the N- or C-terminus of Med11 or 
the C-terminus of Med22 are inviable. Cells lacking 
the N-terminal helix of Med22 or the last 10 amino 
acids of Med11 display a slow growth phenotype. 
 
 
 
Unexpectedly, the bundle fold resembles the previously reported structure of the 
heterodimeric Med7C/21 subcomplex of the middle module (Baumli et al, 2005). The 
Med11/22 and Med7C/21 structures show a root mean square deviation of 3.1 Å over 
121 Cα atoms (Figure 8E). By combining results from HHPred (Söding et al, 2005) and 
secondary structure predictions, we detected a total of six possible heterodimeric four-
helix bundles in Mediator. Nine out of 17 Mediator core subunits and two metazoan-
specific subunits could participate in bundle formation (Figure 10). Heterodimer 
formation has been experimentally verified for Med11/22 in the head (this study), 
Med4/9 (Koschubs et al, 2010), and Med7/21 (Baumli et al, 2005) in the middle, and 
Med2/3 in the tail (Beve et al, 2005). Additional possible bundles include a Med10/14 
heterodimer in the middle module (Koschubs et al, 2010) and a metazoan-specific 
Med28/30 subcomplex. These results establish the four-helix bundle fold as a common 
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building block of Mediator that is apparently found in all modules except for the 
dissociable kinase module. 
 
 
 
Figure 10: A heterodimeric four-helix bundle building block in Mediator 
Schematic depiction of Mediator subunits predicted to share the heterodimeric bundle fold of Med11/22. α-
helices from crystal structures or from predictions (Cuff & Barton, 1999; Jones, 1999; Ouali & King, 2000) 
are indicated as boxes drawn to scale. Helix α1, α2 and C-terminal helical extensions are colored in black, 
grey and white, respectively. Check marks indicate experimentally confirmed heterodimers (co-expression 
and co-purification). Structural homology to the published Med7C/21 structure was predicted with HHPred 
(http://toolkit.lmb.uni-muenchen.de/hhpred) for all listed subunits except the highly divergent Sc subunits 
Med2 and Med3. The p-value and score for the HHPred searches are given. When the human protein 
sequence was used for the HHPred search, the p-values are marked with an asterisk. 
 
 
3.2.4 Essential C-terminal helices extend from the Med11/22 helix bundle 
In the structure of Med7C/21 (Baumli et al, 2005), the four-helix bundle is connected to 
C-terminal helical extensions from both subunits that form a coiled-coil (Figure 8F). The 
C-terminal extensions of Med11 and Med22 lack in the Med11/22 structure, but are 
predicted to each contain an additional helix (Figure 8A and Figure 11). However, in 
contrast to Med7C/21, the C-terminal helices are not predicted to form a coiled-coil, 
and are connected to the bundle through longer, probably flexible linkers. To 
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investigate the importance of the predicted Med11/22 C-terminal helices in vivo, we 
generated several Med11/22 truncation variants (Figure 8A) and tested them in yeast 
complementation assays (Figure 9A and B). Removal of either helix (med111-89 or 
med221-89) or even partial truncation of the Med22 C-terminal helix (med221-108) was 
lethal under standard conditions. Thus, the apparently flexible and helical C-terminal 
extensions from the Med11/22 bundle are required for normal cell growth. 
 
 
 
Figure 11: C-terminal helices in Med11/22 are conserved across species 
Conservation of secondary structure elements in Med11 and Med22 across species (Saccharomyces 
cerevisiae (Sc), Schizosaccharomyces pombe (Sp) and Homo sapiens (Hs)). All secondary structure 
elements from crystal structures (when available) or from consensus secondary structure predictions are 
drawn to scale (boxes, α-helices; lines, ordered but without secondary structure). Helix α1, α2 and  
C-terminal helical extensions are colored in black, grey and white, respectively. 
 
 
3.2.5 Med11/22 extensions bind a Med17 C-terminal domain 
We next asked whether the C-terminal extensions anchor the Med11/22 bundle within 
the head module by an interaction with Med17, the architectural head subunit. We 
could indeed detect in vitro binding of Med11/22 to a soluble C-terminal domain of 
Med17 (Med17C, residues 377-687) (Figure 12A, lane 1 and 3). To map the Med17 
binding determinant in Med11/22, we co-expressed and co-purified truncated 
Med11/22 variants with Med17C in E. coli. Recombinant Med11/22 heterodimers 
containing Med1143-115 could not be co-purified, whereas Med111-89, Med111-105, 
Med2254-121, and Med221-89 all formed stable complexes (Figure 12A). Truncation of 
either predicted C-terminal helix (Figure 12A, lane 6, 7, 10-12) prevented  
co-purification of Med17C with Med11/22, while truncation of the Med22 N-terminus 
(Figure 12A, lane 4) or C-terminal truncations that did not affect the C-terminal helices 
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(Figure 12A, lane 5 and 9) had no effect. We conclude that the C-terminal helices of 
Med11/22 anchor the four-helix bundle to Med17C, and that the C-terminus of Med22 
is absolutely required for this interaction in vitro and in vivo. This is in accordance with 
yeast-two-hybrid results showing that the Sc Med11-Med17 interaction is lost upon C-
terminal truncation of Med11 (Esnault et al, 2008). The consistency of these in vitro 
binding data with the above in vivo phenotyping further suggests that Med11/22 
anchoring to Med17C is essential for cellular growth. 
 
 
 
Figure 12: C-terminal extensions of Med11/22 bind a Med17 C-terminal domain 
(A) Co-expression in E. coli and co-purification of Sc a C-terminal domain of Med17C (residues 377-687) 
with Sc 6His-Med22/Med11 constructs using nickel magnetic beads. A co-purifying contaminant is marked 
with an asterisk. (B) Co-immunoprecipitation of the putative Sp Med11-3HA with Sp Med7-TAP from Sp 
lysate using IgG agarose beads. (C) Co-expression in E. coli and co-purification of Sp Med17 (lanes 1-3) 
and Sp Med17C (residues 257-545; lanes 4-6) with Sp His6-Med22/Med11 constructs using nickel 
magnetic beads.  
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3.2.6 A conserved Med17C/11/22 Mediator subcomplex 
The helix bundle of Med11/22 appears to be conserved among eukaryotes, because 
amino acid residues that constitute the Med11-Med22 interface are conserved (Figure 
8D). However, a Med11 homologue has thus far not been found in Sp (Spahr et al, 
2001). We could however predict a remote Med11 homology in the Sp protein 
SPAC644.10 (Wood et al, 2002). Indeed, Sp SPAC644.10 could be co-
immunoprecipitated with Med7, suggesting it is a Mediator subunit (Figure 12B). 
Amplification and sequencing of the SPAC644.10 cDNA clone revealed the absence of 
an annotated intron, and enabled co-expression and co-purification of recombinant  
Sp SPAC644.10 with Sp Med22 (Figure 12C). This establishes SPAC644.10 as the  
Sp Med11 homologue and confirms the conservation of the Med11/22 bundle. To 
investigate whether the conservation extends to the anchoring of Med11/22 on 
Med17C, we tested whether a trimeric Sp Med17/11/22 subcomplex could be obtained 
after subunit co-expression in E. coli, and this was indeed achieved (Figure 12C, lane 
1). We mapped a soluble C-terminal domain of Sp Med17 (Med17C, residues 257-545) 
that was sufficient for Med11/22 binding (Figure 12C, lane 4). Truncation of the  
C-terminus of Sp Med22 did not affect Med11/22 heterodimer formation, but abolished 
Med17 binding (Figure 12C, lane 3 and 6). Truncation of the C-terminus of Sp Med11 
(Med111-91) had almost no effect (Figure 12C, lane 2 and 5). Thus, the interaction of the 
C-terminal extension from the Med11/22 bundle with Med17C is conserved between 
the distantly related yeast species Sp and Sc, and the Med17C/11/22 subcomplex is 
therefore a conserved architectural unit of the Mediator head. 
 
3.2.7 A highly conserved interaction patch on Med11/22  
Despite the importance of the head module for PIC formation, only few contacts 
between PIC components and head module subunits have been reported. Thus, we 
wanted to identify potential interaction surfaces on Med11/22 that could account for 
contacts to PIC components. Plotting sequence conservation (Figure 13A) and 
electrostatic surface charge (Figure 13B) onto the Med11/22 structure revealed a large, 
highly conserved surface patch with exposed hydrophobic residues on one side of the 
bundle domain. Several known Med11/22 mutations (Esnault et al, 2008; Lee et al, 
1998; Thompson et al, 1993), namely srb6-201 (med22-N59H), srb6-1 (med22-N86H), 
med11-T31A, are located around this patch (Figure 13A and B). 
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Figure 13: Surface of Med11/22 helix bundle. 
(A) Surface conservation of the Med11/22 four-helix bundle. Invariant and conserved residues from yeast 
to human are highlighted in green and yellow, respectively. Residues of Med11 (brown) and Med22 (cyan) 
targeted by mutagenesis in this study and in previous reports are indicated with arrows. The orientation is 
identical to Figure 8C. The two views are related by a 180° rotation around the vertical axis. (B) Surface 
charge distribution. Red, blue and white areas indicate negative, positive and neutral charges, 
respectively. The two views and labeled residues are the same as in (A). 
 
 
Mutations reported to affect interaction of Med11 with Med22 or Med17 (Esnault et al, 
2008; Han et al, 1999), namely med11-V52D, med11-G92S and med11-L73P, are 
however located distant from this patch or in the hydrophobic core (Figure 13A and 
Figure 8D). This suggests that the conserved surface patch is involved in the 
interaction with components of the PIC.  
To investigate the functional importance of this patch we generated structure-based 
surface mutations. Strains carrying double point mutations of adjacent surface residues 
(med11-E17K/L24K, med22-L73E/K80E and med22-K80E/L84E) exhibited various 
degrees of temperature-sensitivity (Figure 14A). The med11-E17K/L24K strain 
exhibited a strong growth defect at all temperatures, similar to med111-105. However, 
unlike the Med11 truncation, the patch mutation did not affect anchoring of Med11/22 
to Med17C in vitro (Figure 14B). Since Med11/22 is essential for Med17 stability 
(Takagi et al, 2006) we purified Mediator from MED11, med111-105 and  
med11-E17K/L24K yeast strains. Mediator composition and integrity appeared 
unchanged on a Coomassie-stained SDS-PAGE (Figure 14C) and was additionally 
confirmed by co-immunoprecipitation and Western Blot (Figure 14D). Thus the 
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phenotype observed for the Med11 mutants is not the result of impaired Mediator 
integrity, but apparently a direct effect of impaired Med11/22 interactions with other 
factors. 
 
 
 
Figure 14: A conserved interaction patch on Med11/22 
(A) Spot dilutions of yeast strains carrying structure-based mutations on the conserved surface patch and 
viable truncations (Figure 2) on YPD plates at 30°C and 37°C. (B) Co-expression in E. coli and co-
purification of Sc Med17C with Sc 6His-Med22/Med11 and Sc 6His-Med22/Med11-E17K/L24K using 
nickel magnetic beads. (C) Mediator tandem affinity purification through Med7-TAP from wild-type, 
med111-105 and med11-E17K/L24K yeast strains. Co-purifying proteins were separated on a 5-12% 
gradient gel (Invitrogen) and bands were stained with Coomassie blue. Mediator subunits and common co-
purifying contaminants are labeled. Med7-CBP marks Med7 after tandem-affinity purification still carrying 
the calmodulin binding protein-tag but lacking the cleaved protein A-tag. (D) Co-immunoprecipitation of Sc 
Med11-3HA (Mediator head module) and Sc Med2 (Mediator tail module) with Sc Med7-TAP (Mediator 
middle module) from wild-type, med111-105 and med11-E17K/L24K yeast strains.  
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3.2.8 Med11/22 is a functionally distinct submodule 
To test whether mutations in Med11/22 affect transcription in vivo, we performed 
genome-wide gene-expression profiling of the med111-105 and med11-E17K/L24K yeast 
strains (Figure 15A).  
 
 
Figure 15: Med11/22 is a functional submodule regulating a specific subset of genes 
(A) Hierarchical cluster diagram (Pearson correlation) of genes exhibiting significantly altered mRNA levels 
(at least 2-fold, vertical axis) for different Mediator mutant strains (horizontal axis). Changes in mRNA 
levels compared to the wild-type strain are depicted in yellow (up), blue (down), or black (no change). (B) 
Pearson correlation matrix for expression profiles of different Mediator mutants (1, very high correlation; 0, 
no correlation; -1, very high anti-correlation). (C) Number of genes significantly (fold change > 2.0,  
p-value < 0.05) up-regulated (yellow) and down-regulated (blue) in med111-105, med11-E17K/L24K and in 
both strains. (D) Comparison of gene expression changes of all mutants analyzed in this study. Number of 
genes significantly (fold change > 2.0, p-value < 0.05) up-regulated (yellow) and down-regulated (blue) is 
shown. 
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The Med11 mutants form a distinct cluster with a Pearson correlation coefficient of 
0.94, correlating only moderately with med20∆ (head module), med2∆ (tail module) and 
with mutations affecting the previously described functional submodule Med7N/31 
(middle module) (Koschubs et al, 2009) (Figure 15B). In total, 604 and 450 genes were 
significantly changed (fold expression change > 2-fold; p-value < 0.05) in med111-105 
and med11-E17K/L24K, respectively. A total of 401 genes were significantly changed 
in both mutants, with 160 genes up-regulated and 241 genes down-regulated (Figure 
15C). The number of significantly changed genes in both Med11 mutant strains is 
higher than in any other Mediator mutant tested (Figure 15D). The effect on gene 
expression is rather pleiotropic without any significant enrichment for specific Gene 
Ontology terms (Boyle et al, 2004). This indicates a distinct function of the Med11/22 
subcomplex in gene regulation, and a more global role in contrast to the more gene-
specific roles of previously reported non-essential Mediator submodules (Koschubs et 
al, 2009; Larivière et al, 2008; van de Peppel et al, 2005).  
 
3.2.9 The Med11/22 surface patch functions in PIC stabilization 
Since Med11 was previously reported to stabilize the TFIIK subcomplex of TFIIH and, 
to some extent, Pol II at promoters (Esnault et al, 2008), we performed chromatin 
immunoprecipitations of Kin28, the kinase subunit of TFIIK, and the Pol II subunit Rpb3 
in wild-type, med111-105, and med11-E17K/L24K strains (Figure 16A). In the mutant 
strains, we observed decreased occupancies for both Kin28 and Rpb3 at active 
promoters, indicating a defect in stable PIC formation. To test whether the decrease is 
a direct effect of impaired Med11/22 function or an indirect effect of global deregulation 
of gene expression, we performed in vitro immobilized template assays with yeast 
nuclear extracts (Figure 16B). PICs were assembled on an immobilized HIS4 yeast 
promoter in a Gcn4-dependent manner, washed and subsequently analyzed by 
Western blot. Consistent with the in vivo results, both mutant extracts displayed a 
decreased occupancy of Pol II after washing. As expected, the occupancy of TFIIB, 
interacting directly with Pol II, is also decreased. Mediator and TFIID, which are 
recruited directly by the transcriptional activator Gcn4 (Herbig et al, 2010), remain 
unaffected. Consistently, nuclear extracts from the Med11 mutant strains were inactive 
in in vitro transcription assays (Figure 16C). Since addition of purified wild-type 
Mediator to the mutant extracts partially rescued the recruitment of the basal machinery 
and consequently also transcriptional activity, the observed defects can be directly 
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linked to Mediator function. These results show that the conserved surface patch on 
the Med11/22 bundle is required for stable PIC formation. 
 
 
Figure 16: Med11/22 is required for stable PIC formation in vitro and in vivo 
(A) Chromatin immunoprecipitation of Rpb3-TAP (Pol II) and Kin28-TAP (TFIIH kinase module) in wild-
type, med111-105 and med11-E17K/L24K strains grown to early exponential phase in YP medium 
containing 2% glucose. Fold enrichment over a heterochromatic control region is shown for the yeast 
promoters of a highly expressed gene (ILV5), a housekeeping gene (ADH1) and a glucose-repressed 
gene (GAL1). (B) In vitro PIC assembly of wild-type, med111-105 and med11-E17K/L24K nuclear extracts 
(NE) on the immobilized HIS4 yeast promoter. PIC formation of mutant extracts was partially rescued by 
adding 2 pmol tandem-affinity purified Mediator complex (TAP-Med) to the nuclear extracts prior to PIC 
assembly. Presence of Pol II (Rpb3 & Rpb11), TFIIB, Mediator (Med17) and TFIID (Taf4) was tested by 
Western Blot. (C) In vitro transcription assay with wild-type, med111-105 and med11-E17K/L24K nuclear 
extracts (NE) on the HIS4 yeast promoter. Order of addition is shown on top. Transcription was partially 
rescued by adding 2 pmol tandem-affinity purified Mediator complex (TAP-Med). 
 
 
3.2.10 Discussion 
To understand the regulatory mechanisms of eukaryotic transcription, a detailed 
structural and functional dissection of the involved multiprotein complexes is required. 
In this study, we extend our previous structure-function analysis of the general 
transcription coactivator Mediator. We combine structural biology, yeast genetics, 
biochemistry, and gene-expression profiling, to define and functionally characterize the 
Mediator subcomplex Med11/22, to provide a more detailed understanding of Mediator 
head module architecture, and to obtain insights into Mediator conservation and 
evolution. We report the structure of a conserved four-helix bundle domain in Med11/22 
that puts reported mutations (Esnault et al, 2008; Han et al, 1999) into a molecular 
                                                                RESULTS AND DISCUSSION 
71 
 
framework and identifies a highly conserved surface patch that is required for a distinct 
widespread function of the Med11/22 subcomplex. 
We suggest that the Med11/22 surface patch mediates an essential interaction with 
TFIIH, because the previously described temperature-sensitive mutation med11-T31A 
(Esnault et al, 2008) locates near the patch. This mutation was shown to decrease 
interaction of Med11 with the TFIIH subunit Rad3 in yeast-two hybrid assays, and 
promoter occupancy of the TFIIH kinase module TFIIK. In contrast to the mutation 
med11-T31A, which was discovered genetically, the mutation med11-E17K/L24K 
reported here was identified based on structural data, and had a strong general growth 
defect that allowed us to conduct functional studies under standard growth conditions. 
Chromatin immunoprecipitation showed a decrease of TFIIK and Pol II occupancies at 
active promoters in vivo, indicating a defect in PIC formation. Yeast nuclear extracts 
from the mutant strain were defective in stable PIC formation and inactive in 
transcription in vitro. The defects result from impairing the function of the Med11/22 
submodule, and not the head module per se, since, in contrast to the reported Med17 
mutant srb4-138 (Ranish et al, 1999), activator-mediated recruitment of Mediator to the 
promoter was not affected. Thus the Med11/22 submodule specifically functions in 
promoting stable PIC formation. We propose that the conserved submodular 
architecture of the Mediator head enables multiple transient interactions with PIC 
components, including TBP (Kang et al, 2001) and TFIIH (Esnault et al, 2008) (Figure 
7), thereby stabilizing the PIC and facilitating open complex formation and initial RNA 
synthesis. 
Another intriguing observation is the presence of up to six related helix bundle folds, to 
which about half of the Mediator core subunits contribute. The presence of related 
bundle domains in different Mediator modules elucidates the evolutionary origin of 
Mediator. Large protein complexes with high functional modularity might generally have 
evolved through duplication of genes encoding dimers (Pereira-Leal et al, 2007). For 
example, the 15-subunit TFIID complex contains five heterodimeric subcomplexes 
interacting through a common histone-fold domain (Gangloff et al, 2001; Leurent et al, 
2002). Subsequent divergent evolution of paralogous subunits could then generate 
asymmetry and diversification of protein interactions for functional specialization. Rapid 
evolution of Mediator by dimer duplication and diversification could explain how it is 
possible that the general transcription machineries are conserved between archaea 
and eukaryotes, whereas Mediator is only present in eukaryotes. 
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3.3 Mediator head module controls preinitiation complex 
formation 
3.3.1 A recombinant head module is functionally active 
In our previous studies we had used structure-function analyses to demonstrate the 
existence of two functionally distinct submodules, Med8C/18/20 (Chapter 3.1) and 
Med11/22 (Chapter 3.2), within the Sc Mediator head module (Figure 14). To further 
characterize the architecture of the Mediator head module and its essential role during 
PIC assembly, structural and functional information on the complete head module is 
required. Therefore, the recombinant coexpression in E. coli and subsequent 
copurification of all seven Sc head subunits was established (Figure 18A; unpublished 
results from the Cramer laboratory). A similar approach using multicistronic expression 
plasmids had already been established for the 7-subunit Sc Mediator middle module 
(Koschubs et al, 2010). 
 
 
 
 
 
 
 
 
 
Figure 17: Model of the submodular 
architecture of Mediator and PIC contacts 
Crystal structures of the essential Med11/22 
four-helix bundle (this work), the previously 
described non-essential Med8C/18/20 
subcomplex (Larivière et al, 2006), and a 
molecular model of the Pol II–TBP–TFIIB–DNA 
promoter closed complex (Kostrewa et al, 2009) 
are drawn to scale. Locations of the general 
factors TFIIF and –H, as determined by 
biochemical probing (Chen et al, 2007; Kim et al, 
2000), are indicated by semi-transparent 
ellipsoids. Mediator head interactions with PIC 
components, namely Med8/18/20 - TBP 
(Larivière et al, 2006) and Med11/22 – TFIIH 
(Esnault et al, 2008), are indicated by arrows. 
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To test the biological activity of the recombinant head module, we performed in vitro 
transcription assays in a nuclear extract from the temperature-sensitive yeast strain 
med17-ts (srb4-138 strain). Whole cell extracts from this strain had been previously 
shown to be impaired in basal and activated transcription in vitro (Takagi & Kornberg, 
2006). Indeed, in vitro transcription in med17-ts nuclear extracts was specifically 
impaired at the non-permissive temperature (Figure 18B, lanes 1 and 2). Addition of 
recombinant 7-subunit head module rescued the defect in activated transcription 
(Figure 18B, lanes 3 and 4). Addition of TAP-purified wild-type Mediator rescued the 
defect to a similar extent (Figure 18C). 
 
 
 
Figure 18: Recombinant Sc Mediator head module is functionally active 
(A) Recombinant Sc Mediator head module preparation. All seven subunit were coexpressed in E. coli and 
subsequently copurified to homogeneity. (B) In vitro transcription in a temperature-sensitive nuclear extract 
prepared from the srb4-138 yeast strain (med17-ts). The recombinant fusion activator Gal4-VP16 was 
added to all samples to monitor activated transcription. In vitro transcription was performed either at the 
permissive temperature (18°C; lane 1 and 3) or the non-permissive temperature (30°C; lane 2 and 4). 
Defect in activated transcription was rescued by addition of 2 pmol recombinant head (rHead). (C) In vitro 
transcription at 30°C as in (A). Addition of approximately2 pmol TAP-purified Mediator (lane 2) rescues to 
transcription to a similar extend as addition of 2 pmol rHead (lane 3). (D) In vitro transcription at 30°C as in 
(A). Additionally Gal4-AH activated transcription was tested. Only addition of 2 pmol recombinant wild-type 
head module (WT; lane 3 and 4) rescued transcription while addition of 2 pmol recombinant head module 
containing a N-terminally truncated Med22 variant (22NΔ; residues 54-121) did not. 
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Furthermore, the rescue of activated transcription in vitro was observed with different 
activation domains (Figure 18D, lanes 1-4) and relied on the functional activity of the 
recombinant head module (Figure 18D, lanes 5 and 6). Similar to a med22NΔ yeast 
nuclear extract, which was unable to support activated transcription in vitro (Chapter 
3.2), addition of a recombinant head module lacking the N-terminus of Med22 did not 
rescue activated transcription (Figure 18D, lane 5 and 6). These results demonstrate 
that the recombinant 7-subunit Sc Mediator head module preparation is biologically 
active and can be used for further biochemical and structural studies.  
 
3.3.2 Preinitiation complex formation requires the head module 
Since activated transcription in a med17-ts nuclear extract depends on a functional 
Mediator head module in vitro, we wanted to determine the factors specifically recruited 
by the Mediator head module. Previous studies had suggested that PIC formation as 
well as Mediator recruitment is abolished in a med17-ts nuclear extract (Ranish et al, 
1999). This makes a distinction between complete Mediator and Mediator head module 
function impossible. However, due to the lack of a recombinant head module for add-
back experiments, secondary effects from extract preparation could not be ruled out. 
Furthermore, the immobilized template assays had been performed with an artificial 
fusion template comprising a modified HIS4 core promoter but lacking the native 
upstream activating sequence. We hypothesized that the upstream activating 
sequence and the respective bound activators could influence the stability of Mediator 
and the basal transcription machinery at the core promoter. Therefore, we performed 
immobilized template assays with yeast nuclear extracts on a native HIS4 promoter 
template. Since the HIS4 UAS comprises several Gcn4 binding sites, we used 
recombinant full-length Gcn4 for activator-dependent PIC assembly. Consistent with 
the in vitro transcription assays (Figure 18B) we performed a 30°C heat step with all 
extracts prior to PIC assembly (Figure 19A). In a wild-type nuclear extract Mediator and 
PIC components were recruited to this native promoter template in a Gcn4 dependent 
manner (Figure 19B, lanes 3 and 4). Consistent with previous reports, TBP was 
recruited independent of the activator through a direct interaction with the TATA box 
(Ranish et al, 1999). Suprisingly and in contrast to previous studies, recruitment of 
Mediator middle and tail modules (Figure 19B, lanes 5) was not affected in the med17-
ts nuclear extract. Only the recruitment of the head module (Med17) and PIC formation 
(Pol II and TFIIB) was abolished. Addition of recombinant 7-subunit head module 
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restored PIC formation (Figure 19B, lanes 6) consistent with the observed rescue of 
activated transcription in vitro (Figure 18). These results suggest that a stable head-
less Mediator (termed Mediator body), comprising the middle and tail module but 
lacking the head module, can be recruited to the promoter by gene specific activators. 
However, only when the head module is bound, a stable PIC is formed.  
 
 
 
Figure 19: PIC formation requires the Mediator Head module 
(A) Order of addition and incubation steps for immobilized template assay. Heat inactivation of 
temperature-sensitive nuclear extracts is done for 10 min at 30°C in the presence of rHead where 
applicable. (B) Immobilized template assays using yeast nuclear extracts from a wild-type strain (WT NE) 
and a temperature-sensitive srb4-138 strain (med17-ts NE) as shown in (A). The native HIS4 core 
promoter and upstream activating sequence were used. Recombinant activator (rGcn4) was added where 
applicable. 5% of the supernatant after heat inactivation and subsequent centrifugation were used as input 
controls (lane 1 and 2).  
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3.3.3 A label-free mass spectrometry approach to study PIC assembly  
To study in more detail PIC assembly in vitro, we established the analysis of 
immobilized template eluates by tandem mass spectrometry and subsequent label-free 
quantitation using spectral counting. A similar method had been previously used to 
characterize RNA polymerases (Mosley et al, 2010) and mammalian Mediator (Paoletti 
et al, 2006). However, in these studies the complexes were purified by chromatography 
and consequently contained only a very limited number of proteins. Based on a 
previous mass spectrometry analysis of immobilized template eluates (Kim et al, 2007), 
we expected our samples to contain more than a hundred different polypeptides, 
including many unspecific DNA binding factors. Therefore, we first validated our label-
free mass spectrometry approach by analyzing three replicates of immobilized template 
assays using the native HIS4 promoter template, recombinant Gcn4 and a wild-type 
yeast nuclear extract. 178 polypeptides were reliably detected in all three replicates, 
comprising 143 nuclear proteins, 23 cytosolic proteins and 12 other or unknown 
proteins (Figure 20). 118 proteins are annotated with the Gene ontology term 
“Transcription” and 85 proteins with the more specific term “Transcription from RNA 
polymerase II promoter”. Proteins not involved in Pol II transcription include DNA repair 
factors, chromosome maintenance factors as well as Pol I and Pol III components. In 
total 10 out of 12 Pol II subunits and 22 out of 25 Mediator subunits were reliably 
detected in all three replicates (Table 21). Similarly, most of the subunits of other 
multiprotein complexes involved in regulation of transcription initiation, like TFIID  
(13 out of 17 subunits), SAGA (18 out of 20 subunits), SLIK (SAGA-like complex,  
15 out of 17 subunits), SWI/SNF (10 out of 12 subunits) and NuA4 (11 out of  
13 subunits) were detected. No factors involved in transcription elongation, mRNA 
processing and termination were found.  
 
 
 
 
 
Figure 20: Localization of proteins identified by tandem mass 
spectrometry  
Proteins were classified according to their localization using the Gene 
ontology term finder tool (http://go.princeton.edu). Other includes factors 
that are associated with specific organelles like mitochondria or that are 
not annotated. 
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Table 21: Mediator and Pol II subunits detected by tandem mass spectrometry analysis of wild-type 
immobilized template eluates 
a specific subunits only found in Pol II 
b shared subunits between Pol I, Pol II and Pol III 
c IT1-3 lists the spectral counts for the respective subunit in three replicates 
d nd = subunit not detected by tandem mass spectrometry 
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It is important to notice that this unbiased quantitation by tandem mass spectrometry 
and spectral counting cannot be used for absolute quantitation. Spectral counts for a 
given protein depend on various factors, including the number of peptides and 
consequently also on the molecular weight of the protein. Small proteins are typically 
more difficult to detect. Therefore, not detecting a protein by tandem mass 
spectrometry does not necessarily mean it is absent. However, a very high linear 
correlation between spectral counts and relative abundance was shown (Zhu et al, 
2010). Consequently, a relative quantification between different samples is possible 
and was used in the following experiments. 
 
3.3.4 Mediator body is recruited independent of head module 
Next, we wanted to confirm the specificity of Mediator recruitment to the promoter 
template. We performed immobilized template assays in a wild-type nuclear extract 
with and without addition of recombinant activator and analyzed the eluates by tandem 
mass spectrometry.  
Consistent with Western blotting analysis (Figure 19B, lanes 3 and 4), Mediator 
subunits were only detected when Gcn4 was added (Figure 21A) confirming an 
activator dependent recruitment of Mediator to the promoter template. Next, we 
performed immobilized template assays in a med17-ts nuclear extract with and without 
addition of recombinant head module. Consistent with Western blotting analysis (Figure 
19B, lanes 5 and 6), Mediator body was recruited to the promoter even in the absence 
of a functional head module (Figure 21A). None of the seven head subunits, but most 
of the middle and tail subunits were detected. At this point, the presence of the kinase 
module remains unconclusive due to the low number of spectral counts in all samples. 
Addition of recombinant head module restored Mediator integrity. Subunits from head, 
middle and tail were detected (Figure 21A). These results clearly demonstrate the 
recruitment of a stable Mediator body comprising the middle, tail and kinase module to 
the promoter even in the absence of functional head module. 
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Figure 21: Analysis of immobilized template assays by tandem mass spectrometry  
Immobilized template assays were performed in wild-type nuclear extracts with and without recombinant 
Gcn4; and in med17-ts nuclear extracts with and without recombinant head module (recombinant Gcn4 
was added to both samples). Activator dependent enrichment (Act) and head dependent enrichment 
(Head) were calculated (1 = positive correlation; 0 = no change; 0 = negative correlation; nd = subunit was 
not detected in any of the samples). (A) spectral counts for each subunit were used for calculation.  
(B) Sum of spectral counts for all unique subunits of the respective complex were used for calculation. In 
addition the gene-specific activators Gcn4 and Rap1, which are directly recruited to the HIS4 UAS are 
shown.  
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3.3.5 Head module is only required for the recruitment of the basal 
machinery 
Next, we asked which factors depend on the head module for promoter recruitment. 
Due to the lack of recombinant head module and appropriate assays, a dissection of 
the recruitment dependencies of various coactivator complex was not possible in the 
past. As expected from previous studies and Western Blot analysis (Figure 19B, lanes 
3 and 4), Pol II recruitment was abolished in med17-ts nuclear extracts. Consistent with 
the previously observed rescue of in vitro transcription (Figure 18) and PIC formation 
(Figure 19B), recruitment of Pol II was restored upon addition of recombinant head 
module  (Figure 21B). Interestingly, recruitment of many cofactors was not affected by 
med17-ts (TFIID, SAGA, NuA4, RSC and Ino80). Only SWI/SNF recruitment showed a 
weak dependence on Mediator head (Figure 21B).  
 
3.3.6 Discussion 
Taken together, our results demonstrate that Mediator is a modular coactivator 
complex, which can be stably recruited by gene-specific activators to a yeast promoter 
even in the absence of the essential head module. This observation is in contrast with 
previous ChIP studies of Mediator promoter occupancy in a med17-ts strain. At the 
non-permissive temperature only the tail module (Ansari et al, 2009) or no Mediator at 
all (Takagi et al, 2006) was observed at the promoter. The lack of add-back 
experiments to rule out secondary effects, the difficulty to chromatin immunoprecipitate 
Mediator at standard growth conditions (Fan & Struhl, 2009) and the monitoring of only 
one representative subunit for each module might explain these differences. 
Furthermore, our results demonstrate that the previously shown interdependent 
recruitment of SAGA, SWI/SNF and Mediator to the core-promoter (Qiu et al, 2005) 
does not require the head module. Our results demonstrate that despite the presence 
of Mediator body, TFIID, SAGA and SWI/SNF at the promoter, PIC formation does not 
occur. Only addition of recombinant head module restores Pol II recruitment and 
consequently PIC formation. This is particularly intriguing since TFIID and SAGA are 
also recruited by activators and were suggested to facilitate alternative PIC assemblies, 
which might not rely on Mediator (reviewed in (Sikorski & Buratowski, 2009)). This 
suggests that although promoters might differ in their dependence on TFIID and SAGA 
(Basehoar et al, 2004; Huisinga & Pugh, 2004) functional Mediator is always required. 
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This is consistent with a previously suggested role of Mediator as a general 
transcription factor (Takagi & Kornberg, 2006) and the global shutdown of Pol II 
transcription in a med17-ts strain (Holstege et al, 1998; Thompson & Young, 1995). 
Another intriguing observation is the presence of TFIID on the HIS4 promoter in the 
absence of Gcn4 and other cofactors (Figure 21B). Previous studies had already 
shown that TFIID can be directly recruited to promoters through interaction with the 
Rap1 transcription factor thereby facilitating PIC formation (Papai et al, 2010). 
Consistently, we found a predicted Rap1 binding site in the HIS4 UAS and detected 
Rap1 in all samples by mass spectrometry (Figure 21B). However, the fact that Rap1 
recruits TFIID without facilitating PIC formation might suggest the existence of a two-
step mechanism during PIC formation. At first, TFIID is loaded to the promoter. 
Afterwards, other gene-specific activators recruit the remaining cofactors like Mediator 
thereby facilitating PIC assembly and transcription initiation. Additional experiments 
and cross-validation of the observations have to be done to validate a sequential PIC 
assembly at the HIS4 promoter.  
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3.4 Additional contributions 
3.4.1 Overview 
The following chapters describe additional experimental results obtained during this 
thesis, which lead to co-author publications. Each chapter starts with a short 
background overview and the relevant biological question. Afterwards, the specific 
experimental contributions to the respective publication are described in detail. 
Additional experiments are only shown and discussed when required for understanding 
the context. All results, detailed methods and a broad discussion of the findings can be 
found in the respective publication and/or thesis of the first author.  
 
3.4.2 Mediator middle submodule Med7N/31 cooperates with TFIIS during 
activated transcription in vitro 
Recombinant coexpression, copurification and subsequent limited proteolysis of the 
trimeric Med7/Med21/Med31 Mediator middle subcomplex had revealed the existence 
of two stable subcomplexes. On the one hand, a dimeric subcomplex comprising 
Med21 and the C-terminus of Med7 (Med7C; residues 103-222) which had been 
previously characterized (Baumli et al, 2005) and on the other hand, a dimeric 
subcomplex comprising Med31 and the N-terminus of Med7 (Med7N; residues 1-83) 
(Figure 22A). The Mediator middle subunit Med31 is particularly interesting since it is 
not essential for yeast viability, but highly conserved from yeast to human (Bourbon, 
2008). Several large-scale studies had already shown that Med31 is required for an 
efficient stress response, e.g. during ethanol, cycloheximide, hydroxyurea and heat 
stress (Alamgir et al, 2010; Teixeira et al, 2009). Furthermore, Med31 had been shown 
to interact genetically with the general transcription factor TFIIS (Malagon et al, 2004) 
and had been implicated to act in conjuction with TFIIS during PIC formation (Guglielmi 
et al, 2007). In this study, we used a combination of structural biology, yeast genetics, 
biochemical assays and global gene expression profiling to demonstrate that 
Med7N/31 is a functional submodule within Mediator required for the expression of a 
specific subset of genes.  
To characterize the function of Med7N/31 during activated transcription and its 
functional cooperativity with TFIIS, we performed in vitro transcription assays with 
yeast nuclear extracts. We used a plasmid-based template comprising the yeast HIS4 
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core promoter and a single upstream Gal4-binding site (Ranish et al, 1999). This 
template enabled us to use two different recombinant fusion activators. Both comprised 
the DNA binding domain of Gal4 and additionally either the activation domain of the 
strong viral activator VP16 (Gal4-VP16) or the acidic yeast activator Gal4 (Gal4-AH).  
 
 
Figure 22: Med7N/31 is a functional submodule in vitro 
(A) Structural overview of the trimeric Med7/21/31 complex architecture. Structures of the non-essential 
Med7N/31 submodule (this study) and the previously described essential Med7C/21 subcomplex (Baumli 
et al, 2005) are drawn to scale. (B) In vitro transcription in a med7N/31Δ yeast nuclear activated with  
Gal4-VP16 is inactive (lane 1). Transcription can be rescued by the addition of TAP-purified Mediator (0.2 
pmol, lane 2) or recombinant Med7N/31 (2–200 pmol, lanes 3–5). 
 
First, we tested whether Med7N/31 is required for activated transcription in vitro. A 
nuclear extract from the med7N/31Δ strain was defective in transcription activated with 
either activator (Figure 22, lane 1; Figure 23B, lane 2). Addition of TAP-purified 
Mediator restored transcription (Figure 22, lane 2), providing a positive control. 
Transcription could also be restored by the addition of recombinant Med7N/31, 
demonstrating that the subcomplex can act in trans without being covalently tethered to 
the Mediator complex (Figure 22, lane 3-5; Figure 23B, lane 2).  
Next, we tested whether Med7N/31 cooperates with TFIIS during activated 
transcription in vitro. Indeed, transcription in a med7N/31Δ nuclear extract that was 
rescued by recombinant Med7N/31 could be enhanced by the addition of recombinant 
TFIIS approximately 4x and 2.5x for Gal4-VP16 (Figure 23A) and Gal4-AH (Figure 
23B) activated transcription, respectively. In wild-type nuclear extracts, TFIIS addition 
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had only a weak stimulatory effect (1.5x; Figure 23D, lane 1-3) and addition of 
Med7N/31 had no effect (Figure 23D, lane 4). Interestingly, addition of TFIIS to a 
med7N/31Δ extract could partially rescue transcription even in the absence of 
recombinant Med7N/31 (Figure 23A, lane 3-4). TFIIS was not limiting in the extracts, as 
a three-fold higher concentration did not further increase the signal. To determine 
whether the observed effect is specific for the Med7N/31 submodule, we prepared a 
nuclear extract from the Mediator head subunit deletion strain med18Δ. Mediator in the 
med18Δ extract specifically lacks the Med18/20 submodule, is inactive for transcription 
in vitro and can be rescued by addition of recombinant Med18/20 in trans (see Chapter 
3.1). In contrast to the med7N/31Δ extract, transcription in the med18Δ nuclear extract 
was not enhanced by TFIIS addition (Figure 23C, lane 3 and 4). Furthermore, the 
med18Δ nuclear extract, which was rescued by the addition of recombinant Med18/20, 
was not further stimulated by the addition of recombinant TFIIS (Figure 23C, lane 5).  
 
 
 
Figure 23: Med7N/31 cooperates with TFIIS during activated transcription in vitro 
(A) In vitro transcription in a med7N/31Δ yeast nuclear extract supplemented with Gal4-VP16 is inactive. 
Addition of recombinant Med7N/31 (r7N/31; 200 pmol; lane 2) could rescue transcription. Addition of 
recombinant TFIIS (rTFIIS; 20 and 60 pmol; lane 3 and 4, respectively) can partially compensate for the 
loss of Med7N/31. (B) In vitro transcription as described for (A) but supplemented with Gal4-AH instead of 
Gal4-VP16. (C) In vitro transcription in a med18Δ yeast nuclear extract supplemented with Gal4-VP16 is 
inactive. Addition of recombinant Med18/20 (r18/20; 20 pmol; lane 2) could rescue transcription. Addition 
of rTFIIS (20 and 60 pmol; lane 3 and 4, respectively) cannot compensate the loss of Med18/20.  
(D) In vitro transcription in a wild-type yeast nuclear extract supplemented with Gal4-VP16 is active (lane 
1). Addition of rTFIIS has only a weak stimulatory effect (20 and 60 pmol; lane 2 and 3, respectively). 
Addition of r18/20 (20 pmol; lane 4) or r7N/31 (200 pmol; lane 5) to a wild-type yeast nuclear extract.had 
no effect. 
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Taken together, our results demonstrate that TFIIS can partially compensate for the 
loss of Med7N/31, and that highest transcript levels required the addition of both TFIIS 
and Med7N/31. These observations were specific for the med7N/31Δ extract, as this 
effect was not obtained in corresponding experiments with a med18Δ extract. These 
results demonstrate the specific functional cooperativity between the Mediator 
submodule Med7N/31 and TFIIS during Pol II transcription initiation in an in vitro 
system.  
                                                                RESULTS AND DISCUSSION 
86 
 
3.4.3 The archetypical activator VP16 targets the Mediator subunit Med25 
through a conserved synergistic use of subdomains 
The herpes simplex virus protein 16 (VP16) is an archetypical acidic activator, which 
activates expression of immediate early viral genes during infection. The C-terminal 
VP16 transactivation domain (TAD; residues 410-490) is widely used for studying 
transcription activation, typically by fusing it to the DNA-binding domain of Gal4  
(Gal4-VP16). The VP16 TAD contains two functional subdomains, H1 (residues  
410-452) and H2 (residues 453-490), which activate transcription independently. VP16 
facilitates PIC formation through targeting several GTF, including TFIIA, TFIIB, TFIID, 
and TFIIH as well as Mediator. The metazoan Mediator subunit Med25 was shown to 
directly interact with VP16 TAD through the activator interaction domain (ACID). In this 
study we solved the NMR structure of Med25 ACID. Chemical shift perturbation 
experiments indicated that VP16 TAD interacts with an extended surface of Med25 
(Figure 24A,B; for details see (Vojnić et al, 2011)). 
 
Figure 24: NMR structure of Med25 and interaction with VP16 TAD 
(A) Ribbon model representation of the Med25 ACID NMR structure. The two views are related by a 180° 
rotation around the vertical axis. Residues that undergo chemical shift changes (Δδ > 0.6 ppm) in the 1H, 
15N HSQC spectra upon VP16 TAD binding onto the ACID structure are highlighted. Rising red color 
intensities correspond to increasing chemical shift changes. Spheres indicate residues with signals that 
show binding in intermediate exchange. (B) Surface representation of the Med25 ACID structure shown in 
the same orientations and colors as in (A). Dashed lines indicate binding surfaces of VP16-H1 and VP16-
H2 activation subdomains as determined by chemical shift perturbation experiments. Interaction “hotspot” 
R466, identified by biochemical assays, is highlighted. 
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To biochemically validate the observations from NMR chemical shift perturbation 
experiments and further characterize the VP16 activation mechanism, we established 
and performed several biochemical assays.  
First, we validated the VP16-ACID interaction with electrophoretic mobility shift assays 
(EMSA). A fluorescently labeled DNA encompassing a Gal4-binding site enabled us to 
monitor formation of a binary complex of Gal4-VP16 with DNA (Figure 25, lane 2), and 
also formation of a ternary complex of the Gal4-VP16/DNA complex with ACID (Figure 
25, lane 4-6). VP16-ACID interaction and consequently ternary complex formation 
could be observed as a supershift in the EMSA. To probe structural determinants in the 
interface, we mutated sites on ACID that showed strong chemical shift perturbations in 
the NMR titration experiments. All ACID variants still bound VP16 in the EMSA (data 
not shown), except the charge-reversal variant R466E, which completely abolished the 
supershift (Figure 25, lane 7-9). These results demonstrate that VP16 binding to ACID 
is robust and probably relies on multiple redundant contacts, and show that ACID 
residue R466 forms a critical interaction ‘hot spot’. This basic residue lies within the H2-
binding face (Figure 24B) and is conserved among ACID homologues.  
 
 
Figure 25: ACID-VP16 interaction assay 
EMSA supershift assay reveals the importance of ACID residue R466 for VP16 binding. The binary 
complex formed by DNA and Gal4-VP16 (lane 2) undergoes a supershift upon addition of increasing 
concentrations of wild-type ACID (lanes 4-6). This supershift is abolished by ACID point mutation R466E 
(lane 7-9). 
 
 
Next, we established a quenching assay to investigate whether the characterized 
VP16-ACID interaction is of functional significance during activated transcription. We 
performed in vitro activated transcription assays with yeast nuclear extracts on the 
                                                                RESULTS AND DISCUSSION 
88 
 
widely used HIS4 promoter with an upstream Gal4-binding site (Ranish et al, 1999). 
The Gal4-VP16 fusion protein is a potent transcriptional activator in this system (Figure 
26A, lane 1). Addition of recombinant ACID quenched the transcription signal through 
an apparent competition with VP16 targets in the yeast extract (Figure 26A, lane 2-4). 
Thus this assay monitored interference of human ACID with functional interactions 
between VP16 and the basal Pol II machinery during activated transcription in vitro. 
The ACID variant R466E had the strongest effect and only quenched transcription to a 
low extent (Figure 26A, lane 5-7), consistent with its critical role in VP16 binding as 
observed in the EMSA assay. Similar experiments with a mammalian B-cell in vitro 
transcription system showed the same effects (Figure 26B; done by collaborators).  
 
Figure 26: VP16 activation is quenched 
by ACID in yeast and mammalian 
system 
(A) ACID quenches VP16 activation in a 
yeast in vitro transcription system. Assays 
were performed with wild-type yeast 
nuclear extracts (lane 1). Increasing 
amounts (10, 100 or 400 pmol) of either 
wild-type ACID (lanes 2-4) or ACID 
variant R466E were added (lanes 5-7). 
Transcription is quenched with 
recombinant ACID, but not with ACID 
variant R466E. (B) ACID quenches VP16 
activation in a mammalian in vitro 
transcription system. Assays were 
performed with B-cell nuclear extracts 
(lane 1). Increasing amounts (530 or 850 
pmol) of either wild-type ACID (lanes 2, 3) 
or specific ACID point mutant variants 
were added (lanes 4-13). ACID R466E 
variant hardly quenches transcription 
(lanes 4, 5), whereas other ACID variants 
do to various extents (lanes 6-13). Data 
are presented as average values of three 
experiments ± S.D., and one 
representative gel is shown. 
 
 
To evaluate the contributions of the VP16 subdomains to transcription activation in 
yeast, we prepared fusion proteins of the Gal4 DNA-binding domain with H1, H2, 
mutated H1 (H1mt) and mutated H2 (H2mt). The mutations targeted functionally 
required hydrophobic residues. Additionally fusions with TAD that was mutated at 
functionally required hydrophobic residues in H1 or H2 (TAD H1mt and TAD H2mt, 
respectively) were prepared. In these assays, H2, but not H1, was alone able to 
activate transcription, although weakly (Figure 27, lanes 6, 7, 15, 16). Consistently, 
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TAD that carried a mutation in H2 supported activated transcription only weakly (Figure 
27, lanes 13, 14), whereas TAD that carried a mutation in H1 strongly activated 
transcription, to nearly the levels of wild-type TAD (Figure 27, lanes 4 and 5). Thus, the 
VP16 TAD subdomains H1 and H2 cooperate during activated transcription in the yeast 
system, with the main contribution coming from H2. 
 
 
Figure 27: VP16 subdomains H1 and H2 activate yeast transcription synergistically 
In vitro transcription with yeast nuclear extracts Transcription in yeast nuclear extracts was monitored in 
the absence (lanes 1, 10) or the presence of different Gal4-VP16 variants, including Gal4 fusions with 
VP16 TAD (lanes 2, 3, 11, 12), TAD carrying the H1 subdomain mutation F442P (H1mt, lanes 4, 5), H1 
(lanes 6, 7), H1mt (lanes 8, 9), TAD carrying the H2 subdomain mutations F473A, F475A, and F479A 
(H2mt, lanes 13, 14), H2 (lanes 15, 16), and H2mt (lanes 17, 18). 
 
 
Taken together, our results characterize the interaction of the metazoan Mediator 
subunit Med25 with the archetypical acidic transcription factor VP16. Strikingly, the 
synergistic activation mode of VP16 is conserved, although it binds different target 
proteins in the yeast and human systems. Yeast Mediator contains neither Med25 nor 
another subunit with ACID homology. In both systems VP16 TAD uses its two 
subdomains H1 and H2 in a synergistic manner, indicating that the yeast transcription 
machinery contains at least two non-overlapping sites capable of binding to the two 
TAD subdomains. Our results contribute to the understanding of how activation 
domains may have evolved to adapt to different unrelated target surfaces. 
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3.4.4 General transcription factor TFIIB controls transcription start site 
selection 
The general transcription factor TFIIB plays an important role during Pol II transcription 
initiation. TFIIB recruits Pol II to the promoter with its N-terminal zinc-ribbon domain (B-
ribbon) (Bushnell et al, 2004; Chen & Hahn, 2003), and at same time contacts TBP and 
DNA through its C-terminal domain (B-core) (Nikolov et al, 1995).  
 
 
Figure 28: Models of the Pol II closed and open complex 
(A) Model of the closed complex (minimal PIC) based on the Pol II-TFIIB crystal structure. DNA template 
and non-template strands are in blue and cyan, respectively. The TATA element is in black and the 
nucleotide in the template strand that represents position 11 in the open complex is shown as a space-
filling model. (B) Model of the open complex (minimal PIC) in the same orientation as in (A). (C) Location 
of nucleotides in DNA template strand initiator consensus sequence and mutations influencing start site 
selection and DNA opening. The open complex model is shown around the active centre. Positions -8 and 
+1 of the template strand are labelled. Position +8 lies adjacent to the B-reader helix that contains residues 
important for TSS selection (Glu 62, Trp 63, Arg 64, Phe 66, pale green spheres). The mobile B-reader 
loop (green-yellow), which contains residues Arg 78 and Val 79 required for initial transcription and TSS 
selection, could reach near positions -1 and +1. Sites of mutations abolishing DNA opening in archaeal 
transcription are shown as salmon spheres. 
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Interestingly, TFIIB has an additional postrecruitment function after PIC formation. 
Mutations in the region connecting the B-ribbon and the B-core had been previously 
shown to affect transcription and transcription start site (TSS) selection, but not PIC 
formation. Several lines of evidence indicated that yeast Pol II scans the DNA for an 
INR sequence motif that defines the TSS. This scanning apparently involves threading 
of the DNA template strand through the template tunnel until an INR is detected by 
sequence-specific interactions. Since the template tunnel passes the active site, INR 
detection must occur near the active site where RNA synthesis is initiated. Previous 
studies had shown that TSS shifts induced by TFIIB mutations depend on the INR 
sequence and that Pol II and TFIIB are alone responsible for TSS selection. 
In this study we solved the crystal structure of a Pol II-TFIIB complex at 4.3 Å and 
proposed a model for the Pol II closed and open complex (Figure 28A and B, 
respectively). Furthermore, two novel structural elements in TFIIB were identified, the 
‘B-linker’ and the ‘B-reader’ element (Figure 28C). In vitro biochemical assays 
demonstrated that the B-linker is involved in promoter opening (not shown). Strikingly, 
the highly conserved B-reader flanks the template tunnel in our open complex model 
(Figure 28B and C), and mutations reported to specifically affect TSS selection mapped 
to this region (Figure 28C). Therefore we hypothesized that the B-reader is involved in 
INR recognition and TSS selection during Pol II scanning.  
To test the scanning model and to demonstrate a B-reader dependent INR recognition 
mechanism, we designed a specialized in vitro transcription template. This template 
comprised the yeast HIS4 core promoter sequence around the TATA box, a single 
upstream Gal4-DNA binding site and a duplicated INR of the yeast SNR14 (Figure 
29A). This fusion template generated transcripts that initiated at the previously mapped 
TSS of the SNR14 promoter (Figure 29B, lane 2). Thus, the INR alone determined the 
TSS, consistent with the scanning model. The yeast INR consensus motif had been 
shown to comprise a conserved residue at position -8, and a CA or TG dinucleotide at 
positions -1/+1 of the non-template strand. Consistently, mutation of the -8 position in 
the first INR of the fusion promoter led to an almost complete loss of the corresponding 
transcript (Figure 29B, lane 3). When both positions -8 and -7 were mutated, 
transcription from the first TSS was totally abolished (Figure 29B, lane 4). Mutation of 
the TATA box abolished transcription from all TSS (Figure 29B, lane 5). In the open 
complex model, the complementary template T residue at -8 is adjacent to the B-reader 
(Figure 28B and C). To test mutations in TFIIB, we prepared a nuclear extract from a 
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strain carrying a temperature-sensitive mutation in TFIIB (TFIIB-ts). This extract is 
inactive in in vitro transcription but can be restored by addition of recombinant TFIIB 
(Figure 29C). We used this system to test several mutant variants of TFIIB in their 
ability to rescue in vitro transcription and changes in TSS selection. Consistent with the 
modelling and published data, mutation of the respective B-reader residues decreased 
transcription efficiency and in some cases led to detectable changes in TSS selection 
(Figure 29D).   
Taken together, our results demonstrate that the INR alone determines TSS selection 
and that the -8 position is important for the INR recognition. Furthermore, our results 
suggest that the INR is recognized with the help of the B-reader during Pol II scanning. 
 
 
 
Figure 29: B-reader and transcription start site selection 
(A) Design of the fusion promoter template HIS4-SNR14. In promoters A[-8]C and A[-7, -8]C, adenines at 
position -8 or at -8 and -7, respectively, relative to the first TSS were replaced by cytosines (white). Arrows 
indicate in vitro TSSs in HIS4 and HIS4-SNR14 fusion promoters, respectively. (B) Three different TSSs 
are used during in vitro transcription in yeast extracts with the HIS4-SNR14 fusion promoter (lane 2). The 
mutations in promoters A[-8]C and A[-7,-8]C gradually eliminate recognition of the first TSS (lanes 3 and 
4). (C) Nuclear extract from a temperature-sensitive yeast strain with a mutation in TFIIB (TFIIBts) is 
essentially inactive in in vitro transcription (lane 3). Activity is restored when recombinant wild-type (WT) 
TFIIB is added (lane 5). Asterisk denotes a non-specific band. The HIS4-SNR14 template and the location 
of the observed TSSs (+1 upstream (u), +1 downstream (d), +7 downstream) (D) Mutations in the yeast B-
reader residues Arg 64, Phe 66, Arg 78 and Val 79, but not Asn 68, lead to TSS shifts. 
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4 Conclusion and Outlook 
The head module of the general coactivator complex Mediator plays an important role 
during Pol II transcription initiation. In this study, we used a structure-function-system 
correlation, combining X-ray crystallography, yeast genetics, biochemical assays, 
chromatin immunoprecipitation, genome-wide expression profiling and label-free mass 
spectrometry, to further characterize its architecture and function. Small-structure 
guided system perturbations were used to dissect the distinct roles of the Med8C/18/20 
and Med11/22 submodules without affecting head module integrity per se. This 
approach is in general superior to classic gene deletion studies since it does not affect 
complex integrity. Therefore, effects can be directly attributed to the mutated subunit. A 
similar approach was established for studying recombinant 7-subunit head modules. In 
the future, the combination of functional in vitro assays supplemented with recombinant 
subcomplexes and an unbiased analysis of promoter-associated factors by label-free 
tandem mass spectrometry will enable a precise dissection of Mediator function.  
 
Future goals include the following: 
 
1) Further characterization of Med11/22 function during Pol II transcription 
In this study, structure-guided Med11/22 mutations were shown to affect the 
expression of at least 400 genes. In contrast, previous studies had shown that 
the med17-ts mutation in the head module affects the expression of most if not 
all genes. To test whether Med11/22 is also globally required for gene 
expression, the structure-based temperature-sensitive mutation med11-
L73K/K80E could be used. Global synthesis rates of med17-ts and med11-
L73K/K80E could be determined and compared by dynamic transcriptome 
analysis (Miller et al, 2011). Directly after heat inactivation the nascent 
transcripts would be labeled and subsequently analyzed. This approach 
minimizes secondary effects, since the mutation has no effect on gene 
expression at the permissive temperature.  
Furthermore, site-directing crosslinking approaches could be used to 
characterize the interaction surface of Med11/22. Site-directed crosslinkers 
could be easily introduced into the recombinant head module. In vitro PIC 
assembly with a med17-ts nuclear extract and the modified recombinant head 
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module followed by crosslinking could potentially confirm the reported yeast-
two-hybrid interaction with TFIIH and identify additional interaction partners.  
 
2) Functional characterization of other head module subunits 
The versatile in vitro assays based on med17-ts nuclear extracts and 
recombinant Mediator head module can be used in the future to characterize 
the remaining essential subunits, Med6, Med8 and Med17. Mutant variants of 
the recombinant head module could be generated and tested for the rescue of 
in vitro transcription similar to the approach used to characterize TFIIB (see 
Chapter 3.4.4). Furthermore PIC assembly of various mutants could be tested. 
Similar to the approach described above, site-directed crosslinkers could be 
introduced to identify interaction partners in Pol II and the GTF.  
 
3) Structural and functional studies of recombinant core Mediator  
Recombinant coexpression and copurification strategies for Mediator head and 
middle modules are already available in the laboratory. In the future, a similar 
strategy could be used to obtain recombinant core Mediator comprising all 
essential subunits. This complex could be used for high-resolution electron 
microscopy and crosslinking mass spectrometry. Fusion of recombinant core 
Mediator with a DNA-binding domain, like the bacterial lexA-DNA binding 
domain, could be used to study the role of Mediator during PIC formation 
isolated from other coactivator complexes.  
 
4) Identification and characterization of inter-module interactions within Mediator 
Although the architecture of individual Mediator modules has been 
characterized in detail (Koschubs et al, 2010; Takagi et al, 2006), the inter-
module interactions remain largely unclear. In this study, we demonstrated the 
existence of a stable head-less Mediator (termed Mediator body). A 
recombinant head module can associate with Mediator body and thus rescue 
Mediator function. In the future, mutant variants of the recombinant head 
module could be used to indentify the molecular interaction between Mediator 
head and body.  
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5) Characterization of the interplay between Mediator and other coactivators at 
different Pol II promoter classes 
Recent genome-wide studies had suggested that different Pol II promoters are 
dominated by different coactivator complexes (Basehoar et al, 2004; Huisinga & 
Pugh, 2004). While TATA box containing promoters rely on SAGA, TATA-less 
promoters rely on TFIID for activation. In this study, we demonstrated that 
several coactivator complexes including Mediator, SAGA and TFIID, are 
recruited to a TATA box containing yeast promoter in vitro. In the future, a 
TATA-less promoter template for immobilized template assays could be 
established. Differences in factor recruitment as well as the role of Mediator 
could be determined using the unbiased label-free mass spectrometry approach 
established in this study.  
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